[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fq7frlEB4YU9bIdWy9fiYOfXn9GRACnrUbv3DEkPdNMk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":83,"rows":90},"ImmunityBio, Inc.",[4],80,false,22,8,3654,49,0,[14,17,20,22,25,27,29,31],{"name":15,"count":16},"Pancreatic Cancer",6,{"name":18,"count":19},"COVID-19",4,{"name":21,"count":19},"Covid19",{"name":23,"count":24},"NMIBC",3,{"name":26,"count":24},"Merkel Cell Carcinoma",{"name":28,"count":24},"Sepsis",{"name":30,"count":24},"Lymphopenia",{"name":32,"count":33},"Solid Tumor",2,[35,40,45,50,55,60,65,69,73,78],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT03022825","QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer","2024-10-01","N-803 and BCG",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT04390399","Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer","2025-10-13","N-803",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05618925","Study for Subjects With Relapsed\u002FRefractory Non- Hodgkin Lymphoma","2026-05-15","N803",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT04898543","QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors","2026-05-31","M-CENK, Suspension for Infusion, Cryopreserved",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT07123727","A Study to Examine Anktiva for the Treatment of COVID-19.","2026-07","Anktiva",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT02138734","A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer","2026-09-30","BCG",{"nctId":66,"briefTitle":67,"date":68,"intervention":44},"NCT07108036","A Study to Assess Anktiva in Patients With Long Covid-19.","2026-10",{"nctId":70,"briefTitle":71,"date":72,"intervention":39},"NCT06829823","Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer","2026-11",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06710288","A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer","2027-05","Gemcitabine",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT07125872","Study of Relapsed\u002F Refractory B-cell Non- Hodgkin Lymphoma","2027-05-25","CD19 t-haNK- IV Administration",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,300,498,524,546,585,603,621,639,657,675,693,747,888,929,967,993,1018,1047,1141,1223,1298,1341,1367,1385,1403,1446,1464,1482,1500,1518,1536,1554,1572,1590,1608,1626,1644,1667,1688,1734,1760,1778,1796,1814,1832,1850,1868,1886,1910,1973,2009,2027,2045,2063,2081,2099,2117,2135,2153,2171,2189,2207,2225,2243,2261,2279,2381,2467,2553,2639,2721,2803,2885,2967,3034,3100,3154,3204,3254,3300,3338,3376,3410,3440,3487,3517,3543,3592,3614,3636,3658,3693,3715,3737,3762,3780,3798,3816,3844,3862,3880,3898,3916,3942,3960,3978,3996,4014,4032,4059,4077,4095,4113,4131,4149,4167,4185,4203,4221,4245,4269,4287,4310,4332],{"intervention":44,"totalTrials":92,"cells":93},17,{"EARLY_PHASE1":94,"PHASE1":96,"PHASE2":127,"PHASE3":272,"PHASE4":296,"NA":298},{"trials":95,"activeCount":12},[],{"trials":97,"activeCount":113,"soonestReadout":53},[98,106,116],{"nctId":51,"briefTitle":52,"status":99,"phases":100,"primaryCompletion":53,"completion":53,"start":101,"enrollment":102,"conditions":103,"interventions":105},"ACTIVE_NOT_RECRUITING",[85],"2021-06-21",50,[104],"Metastatic Solid Tumor",[54,44],{"nctId":107,"briefTitle":108,"status":109,"phases":110,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":115},"NCT04385849","Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19","TERMINATED",[85],"2020-07-25","2020-07-22",1,[18],[44],{"nctId":117,"briefTitle":118,"status":119,"phases":120,"primaryCompletion":121,"completion":121,"start":122,"enrollment":123,"conditions":124,"interventions":126},"NCT06040918","Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis","COMPLETED",[85],"2024-09-03","2023-10-04",10,[125],"Healthy Subjects",[44],{"trials":128,"activeCount":271,"soonestReadout":43},[129,158,172,185,198,211,219,231,237,244,250,261],{"nctId":130,"briefTitle":131,"status":109,"phases":132,"primaryCompletion":133,"completion":134,"start":135,"enrollment":19,"conditions":136,"interventions":138},"NCT03387111","QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed",[85,86],"2019-04-17","2021-01-11","2018-01-09",[137],"Squamous Cell Carcinoma",[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,44],"Aldoxorubicin HCl","ETBX-011","ETBX-021","ETBX-051","ETBX-061","GI-4000","GI-6207","GI-6301","haNK for","Avelumab","bevacizumab","Capecitabine","Cetuximab","Cisplatin","Cyclophosphamide","Fluorouracil","Leucovorin","nab-Paclitaxel","Necitumumab",{"nctId":159,"briefTitle":160,"status":161,"phases":162,"primaryCompletion":163,"completion":164,"start":165,"enrollment":166,"conditions":167,"interventions":169},"NCT06061809","N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma","RECRUITING",[86],"2029-12-31","2030-12-31","2024-08-07",34,[168],"Glioblastoma",[170,171,44],"Bevacizumab","PD-L1 t-haNK",{"nctId":173,"briefTitle":174,"status":109,"phases":175,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":180,"interventions":182},"NCT03387085","QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.",[85,86],"2020-09-11","2024-01-16","2018-03-19",9,[181],"Triple Negative Breast Cancer",[139,44,140,142,143,144,145,146,147,183,149,150,152,153,184,155,156],"avelumab","5-Fluorouracil",{"nctId":186,"briefTitle":187,"status":188,"phases":189,"primaryCompletion":190,"completion":191,"start":192,"enrollment":193,"conditions":194,"interventions":196},"NCT07477366","Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma","NOT_YET_RECRUITING",[86],"2027-12","2028-12","2026-04",20,[195],"Relapsed B-Cell Non-Hodgkin Lymphoma",[82,44,197],"rituximab",{"nctId":199,"briefTitle":200,"status":201,"phases":202,"primaryCompletion":203,"completion":204,"start":205,"enrollment":12,"conditions":206,"interventions":208},"NCT06765954","Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.","WITHDRAWN",[86],"2031-01-31","2031-06-30","2025-12-01",[207],"High-risk Prostate Cancer",[44,209,210],"ETBX-071","M-CENK",{"nctId":41,"briefTitle":42,"status":99,"phases":212,"primaryCompletion":43,"completion":53,"start":213,"enrollment":214,"conditions":215,"interventions":216},[86],"2020-07-21",328,[15],[44,139,171,217,77,153,184,155,218],"Nab-paclitaxel","Irinotecan liposome",{"nctId":220,"briefTitle":221,"status":201,"phases":222,"primaryCompletion":223,"completion":223,"start":224,"enrollment":12,"conditions":225,"interventions":228},"NCT03563170","QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine",[85,86],"2019-08-23","2018-05-25",[226,227],"Hepatocellular Carcinoma Non-resectable","Hepatocellular Carcinoma Recurrent",[140,144,147,183,150,153,184,155,156,229,230,142,143,145,146,151,44],"Sorafenib","Aldoxorubicin hydrochloride",{"nctId":74,"briefTitle":75,"status":161,"phases":232,"primaryCompletion":76,"completion":76,"start":233,"enrollment":193,"conditions":234,"interventions":236},[86],"2024-11-06",[235],"Platinum-resistant Ovarian Cancer",[77,44,210],{"nctId":238,"briefTitle":239,"status":201,"phases":240,"primaryCompletion":203,"completion":204,"start":241,"enrollment":12,"conditions":242,"interventions":243},"NCT06765902","Immunotherapy Before and After Surgery",[86],"2025-12-15",[207],[44,209,210],{"nctId":66,"briefTitle":67,"status":161,"phases":245,"primaryCompletion":68,"completion":68,"start":246,"enrollment":193,"conditions":247,"interventions":249},[86],"2025-11-14",[248],"Long COVID",[44],{"nctId":251,"briefTitle":252,"status":109,"phases":253,"primaryCompletion":254,"completion":255,"start":256,"enrollment":24,"conditions":257,"interventions":259},"NCT04927884","A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies",[85,86],"2022-09-13","2022-12-12","2021-09-08",[258],"Advanced Triple Negative Breast Cancer",[44,171,260,153],"Sacituzumab Govitecan-Hziy",{"nctId":262,"briefTitle":263,"status":109,"phases":264,"primaryCompletion":265,"completion":266,"start":267,"enrollment":179,"conditions":268,"interventions":269},"NCT03853317","QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy",[86],"2021-09-29","2022-09-19","2020-02-19",[26],[148,44,270],"haNK™",5,{"trials":273,"activeCount":33,"soonestReadout":38},[274,282],{"nctId":36,"briefTitle":37,"status":99,"phases":275,"primaryCompletion":38,"completion":276,"start":277,"enrollment":278,"conditions":279,"interventions":281},[86,87],"2029-03-01","2017-06-02",190,[280],"Bladder Cancer",[39,44],{"nctId":283,"briefTitle":284,"status":161,"phases":285,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":290,"interventions":292},"NCT06745908","Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In",[87],"2028-09","2029-01","2025-10-01",507,[291],"NSCLC Stage IV",[44,293,294,295],"Tislelizumab","Docetaxel","Prior failed checkpoint inhibitor",{"trials":297,"activeCount":12},[],{"trials":299,"activeCount":12},[],{"intervention":156,"totalTrials":193,"cells":301},{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":475,"PHASE4":494,"NA":496},{"trials":303,"activeCount":12},[],{"trials":305,"activeCount":12},[],{"trials":307,"activeCount":113,"soonestReadout":43},[308,320,324,338,348,352,361,365,377,394,398,409,417,425,436,444,452,458,466],{"nctId":309,"briefTitle":310,"status":109,"phases":311,"primaryCompletion":312,"completion":313,"start":314,"enrollment":19,"conditions":315,"interventions":316},"NCT03387098","QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy",[85,86],"2018-09-12","2019-01-15","2017-12-28",[15],[139,317,140,144,147,183,149,150,153,154,155,156,318,319],"ALT-803","lovaza","Oxaliplatin",{"nctId":130,"briefTitle":131,"status":109,"phases":321,"primaryCompletion":133,"completion":134,"start":135,"enrollment":19,"conditions":322,"interventions":323},[85,86],[137],[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,44],{"nctId":325,"briefTitle":326,"status":109,"phases":327,"primaryCompletion":328,"completion":329,"start":330,"enrollment":33,"conditions":331,"interventions":334},"NCT03563157","QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine",[85,86],"2019-04-21","2019-08-21","2018-09-28",[332,333],"Colorectal Cancer Metastatic","mCRC",[335,317,140,141,142,143,144,145,146,336,148,150,151,153,184,155,217,319,337],"Aldoxorubicin Hydrochloride","haNK","Regorafenib",{"nctId":339,"briefTitle":340,"status":201,"phases":341,"primaryCompletion":342,"completion":343,"start":344,"enrollment":12,"conditions":345,"interventions":347},"NCT03563144","QUILT-3.088: NANT Pancreatic Cancer Vaccine",[86],"2019-12-30","2022-02-09","2018-08",[346],"Metastatic Pancreatic Cancer",[77,217,139,317,140,141,142,143,144,145,146,336,148,170,150,153,184,155,319],{"nctId":173,"briefTitle":174,"status":109,"phases":349,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":350,"interventions":351},[85,86],[181],[139,44,140,142,143,144,145,146,147,183,149,150,152,153,184,155,156],{"nctId":353,"briefTitle":354,"status":109,"phases":355,"primaryCompletion":356,"completion":357,"start":358,"enrollment":16,"conditions":359,"interventions":360},"NCT03329248","QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy",[85,86],"2018-08-13","2019-11-01","2017-11-06",[15],[317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":41,"briefTitle":42,"status":99,"phases":362,"primaryCompletion":43,"completion":53,"start":213,"enrollment":214,"conditions":363,"interventions":364},[86],[15],[44,139,171,217,77,153,184,155,218],{"nctId":366,"briefTitle":367,"status":201,"phases":368,"primaryCompletion":344,"completion":369,"start":370,"enrollment":12,"conditions":371,"interventions":373},"NCT03574649","QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer",[86],"2018-08-22","2018-06",[372],"Non Small Cell Lung Cancer",[217,152,374,153,140,142,143,144,146,375,148,317,336,294,376],"5Fluorouracil","Aldoxorubicin","carboplatin",{"nctId":378,"briefTitle":379,"status":201,"phases":380,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":384,"interventions":386},"NCT03197571","QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1\u002FPD-L1 Therapy",[85,86],"2019-01","2021-12-28","2017-12",[385],"Urothelial Carcinoma",[183,149,387,388,389,374,390,391,392,393,317,140,141,142,143,144,145,146,336],"capecitabine","cisplatin","cyclophosphamide","fulvestrant","leucovorin","nab-paclitaxel","Lovaza",{"nctId":220,"briefTitle":221,"status":201,"phases":395,"primaryCompletion":223,"completion":223,"start":224,"enrollment":12,"conditions":396,"interventions":397},[85,86],[226,227],[140,144,147,183,150,153,184,155,156,229,230,142,143,145,146,151,44],{"nctId":399,"briefTitle":400,"status":119,"phases":401,"primaryCompletion":402,"completion":402,"start":403,"enrollment":404,"conditions":405,"interventions":407},"NCT05304936","HCW9218 for Advanced Pancreatic Cancer",[85,86],"2025-02-15","2022-10-17",21,[406],"Advanced Pancreatic Carcinoma",[408,77,217],"HCW9218",{"nctId":410,"briefTitle":411,"status":109,"phases":412,"primaryCompletion":133,"completion":413,"start":414,"enrollment":24,"conditions":415,"interventions":416},"NCT03586869","QUILT-3.080: NANT Pancreatic Cancer Vaccine",[85,86],"2019-08-01","2018-07-17",[15],[139,317,140,141,142,143,144,145,146,147,149,150,153,154,155,156,319,148],{"nctId":418,"briefTitle":419,"status":201,"phases":420,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":421,"interventions":422},"NCT03167164","QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy",[85,86],[26],[148,170,150,152,153,423,155,156,424,317,142,143,146,336],"5-fluorouracil","omega-3-acid ethyl esters",{"nctId":426,"briefTitle":427,"status":201,"phases":428,"primaryCompletion":429,"completion":343,"start":430,"enrollment":12,"conditions":431,"interventions":433},"NCT03554109","QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine",[86],"2020-06","2018-09",[432],"Triple Negative Breast Cancer (TNBC)",[155,184,139,156,140,142,143,144,145,146,148,317,336,153,434,435],"Doxorubicin HCL","paclitaxel",{"nctId":437,"briefTitle":438,"status":201,"phases":439,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":440,"interventions":442},"NCT03169764","QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1\u002FPD-L1 Therapy",[85,86],[441],"Head and Neck Squamous Cell Carcinoma",[148,170,150,151,152,389,184,390,391,392,443,393,317,140,141,142,143,144,145,146,336],"nivolumab",{"nctId":445,"briefTitle":446,"status":201,"phases":447,"primaryCompletion":381,"completion":448,"start":383,"enrollment":12,"conditions":449,"interventions":451},"NCT03169790","QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL",[85,86],"2021-12-23",[450],"Non Hodgkin Lymphoma",[183,149,387,389,184,391,392,393,319,197,317,143,336],{"nctId":453,"briefTitle":454,"status":201,"phases":455,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":456,"interventions":457},"NCT03175666","QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy",[85,86],[181],[183,149,387,388,389,184,155,392,393,317,140,142,143,144,145,146,336],{"nctId":459,"briefTitle":460,"status":201,"phases":461,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":462,"interventions":464},"NCT03167177","QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1\u002FPD-L1 Therapy",[85,86],[463],"Melanoma",[148,170,150,152,153,423,155,392,465,424,317,140,142,143,145,146,336],"Nivolumab",{"nctId":467,"briefTitle":468,"status":109,"phases":469,"primaryCompletion":470,"completion":357,"start":471,"enrollment":24,"conditions":472,"interventions":473},"NCT03136406","QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy",[85,86],"2017-11-22","2017-08-11",[15],[153,319,150,184,155,392,149,183,317,474,140,144],"aNK for",{"trials":476,"activeCount":113,"soonestReadout":481},[477],{"nctId":478,"briefTitle":479,"status":188,"phases":480,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":485,"interventions":488},"NCT07524257","Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC",[87],"2029-05-15","2029-12-30","2026-05-29",494,[486,487],"NSCLC (Advanced Non-small Cell Lung Cancer)","Metastatic NSCLC",[489,490,491,217,492,493],"Drug: Nogapendekin alfa inbakicept","Pembrolizumab","Cisplatin or Carboplatin","Nab-paclitaxel OR Paclitaxel OR Docetaxel","Pemetrexed",{"trials":495,"activeCount":12},[],{"trials":497,"activeCount":12},[],{"intervention":39,"totalTrials":33,"cells":499},{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":504,"PHASE3":514,"PHASE4":520,"NA":522},{"trials":501,"activeCount":12},[],{"trials":503,"activeCount":12},[],{"trials":505,"activeCount":113,"soonestReadout":72},[506],{"nctId":70,"briefTitle":71,"status":188,"phases":507,"primaryCompletion":72,"completion":508,"start":509,"enrollment":193,"conditions":510,"interventions":512},[86],"2029-11","2025-11",[511],"Non-muscle Invasive Bladder Cancer (NMIBC)",[39,513],"N-803 and Gemcitabine",{"trials":515,"activeCount":113,"soonestReadout":38},[516],{"nctId":36,"briefTitle":37,"status":99,"phases":517,"primaryCompletion":38,"completion":276,"start":277,"enrollment":278,"conditions":518,"interventions":519},[86,87],[280],[39,44],{"trials":521,"activeCount":12},[],{"trials":523,"activeCount":12},[],{"intervention":294,"totalTrials":33,"cells":525},{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":530,"PHASE3":536,"PHASE4":542,"NA":544},{"trials":527,"activeCount":12},[],{"trials":529,"activeCount":12},[],{"trials":531,"activeCount":12},[532],{"nctId":366,"briefTitle":367,"status":201,"phases":533,"primaryCompletion":344,"completion":369,"start":370,"enrollment":12,"conditions":534,"interventions":535},[86],[372],[217,152,374,153,140,142,143,144,146,375,148,317,336,294,376],{"trials":537,"activeCount":113,"soonestReadout":286},[538],{"nctId":283,"briefTitle":284,"status":161,"phases":539,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":540,"interventions":541},[87],[291],[44,293,294,295],{"trials":543,"activeCount":12},[],{"trials":545,"activeCount":12},[],{"intervention":490,"totalTrials":33,"cells":547},{"EARLY_PHASE1":548,"PHASE1":550,"PHASE2":552,"PHASE3":554,"PHASE4":581,"NA":583},{"trials":549,"activeCount":12},[],{"trials":551,"activeCount":12},[],{"trials":553,"activeCount":12},[],{"trials":555,"activeCount":113,"soonestReadout":481},[556,577],{"nctId":557,"briefTitle":558,"status":109,"phases":559,"primaryCompletion":43,"completion":43,"start":560,"enrollment":561,"conditions":562,"interventions":563},"NCT03520686","Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer",[87],"2018-05-18",102,[372],[564,565,566,567,568,569,570,490,571,572,573,574,575,576],"NAI + Pembrolizumab","NAI + Nivolumab + Ipilimumab","NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel","Cisplatin\u002FCarboplatin + Pemetrexed + Pembrolizumab + NAI","Cisplatin\u002FCarboplatin + Pemetrexed + Atezolizumab + NAI","Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAI","Carboplatin + Nab-paclitaxel + Atezolizumab + NAI","Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel","Drug: Cisplatin\u002FCarboplatin and Pemetrexed plus Pembrolizumab","Cisplatin\u002FCarboplatin and Pemetrexed plus Atezolizumab","Carboplatin and Paclitaxel plus Atezolizumab and Bevacizumab","Carboplatin and Nab-paclitaxel plus Atezolizumab","Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel",{"nctId":478,"briefTitle":479,"status":188,"phases":578,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":579,"interventions":580},[87],[486,487],[489,490,491,217,492,493],{"trials":582,"activeCount":12},[],{"trials":584,"activeCount":12},[],{"intervention":293,"totalTrials":113,"cells":586},{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":591,"PHASE3":593,"PHASE4":599,"NA":601},{"trials":588,"activeCount":12},[],{"trials":590,"activeCount":12},[],{"trials":592,"activeCount":12},[],{"trials":594,"activeCount":113,"soonestReadout":286},[595],{"nctId":283,"briefTitle":284,"status":161,"phases":596,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":597,"interventions":598},[87],[291],[44,293,294,295],{"trials":600,"activeCount":12},[],{"trials":602,"activeCount":12},[],{"intervention":295,"totalTrials":113,"cells":604},{"EARLY_PHASE1":605,"PHASE1":607,"PHASE2":609,"PHASE3":611,"PHASE4":617,"NA":619},{"trials":606,"activeCount":12},[],{"trials":608,"activeCount":12},[],{"trials":610,"activeCount":12},[],{"trials":612,"activeCount":113,"soonestReadout":286},[613],{"nctId":283,"briefTitle":284,"status":161,"phases":614,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":615,"interventions":616},[87],[291],[44,293,294,295],{"trials":618,"activeCount":12},[],{"trials":620,"activeCount":12},[],{"intervention":489,"totalTrials":113,"cells":622},{"EARLY_PHASE1":623,"PHASE1":625,"PHASE2":627,"PHASE3":629,"PHASE4":635,"NA":637},{"trials":624,"activeCount":12},[],{"trials":626,"activeCount":12},[],{"trials":628,"activeCount":12},[],{"trials":630,"activeCount":113,"soonestReadout":481},[631],{"nctId":478,"briefTitle":479,"status":188,"phases":632,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":633,"interventions":634},[87],[486,487],[489,490,491,217,492,493],{"trials":636,"activeCount":12},[],{"trials":638,"activeCount":12},[],{"intervention":491,"totalTrials":113,"cells":640},{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":645,"PHASE3":647,"PHASE4":653,"NA":655},{"trials":642,"activeCount":12},[],{"trials":644,"activeCount":12},[],{"trials":646,"activeCount":12},[],{"trials":648,"activeCount":113,"soonestReadout":481},[649],{"nctId":478,"briefTitle":479,"status":188,"phases":650,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":651,"interventions":652},[87],[486,487],[489,490,491,217,492,493],{"trials":654,"activeCount":12},[],{"trials":656,"activeCount":12},[],{"intervention":492,"totalTrials":113,"cells":658},{"EARLY_PHASE1":659,"PHASE1":661,"PHASE2":663,"PHASE3":665,"PHASE4":671,"NA":673},{"trials":660,"activeCount":12},[],{"trials":662,"activeCount":12},[],{"trials":664,"activeCount":12},[],{"trials":666,"activeCount":113,"soonestReadout":481},[667],{"nctId":478,"briefTitle":479,"status":188,"phases":668,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":669,"interventions":670},[87],[486,487],[489,490,491,217,492,493],{"trials":672,"activeCount":12},[],{"trials":674,"activeCount":12},[],{"intervention":493,"totalTrials":113,"cells":676},{"EARLY_PHASE1":677,"PHASE1":679,"PHASE2":681,"PHASE3":683,"PHASE4":689,"NA":691},{"trials":678,"activeCount":12},[],{"trials":680,"activeCount":12},[],{"trials":682,"activeCount":12},[],{"trials":684,"activeCount":113,"soonestReadout":481},[685],{"nctId":478,"briefTitle":479,"status":188,"phases":686,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":687,"interventions":688},[87],[486,487],[489,490,491,217,492,493],{"trials":690,"activeCount":12},[],{"trials":692,"activeCount":12},[],{"intervention":694,"totalTrials":24,"cells":695},"Nogapendekin alfa inbakicept",{"EARLY_PHASE1":696,"PHASE1":698,"PHASE2":715,"PHASE3":729,"PHASE4":743,"NA":745},{"trials":697,"activeCount":12},[],{"trials":699,"activeCount":113,"soonestReadout":704},[700],{"nctId":701,"briefTitle":702,"status":188,"phases":703,"primaryCompletion":704,"completion":705,"start":706,"enrollment":707,"conditions":708,"interventions":710},"NCT07488884","Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer",[85],"2027-06-01","2029-06-01","2026-06-01",30,[709,15],"Pancreatic Cancer Resectable",[711,712,713,714],"Nogapendekin Alfa Inbakicept","Sotevtamab","Zabadinostat","Nab paclitaxel \u002F gemcitabine",{"trials":716,"activeCount":113,"soonestReadout":721},[717],{"nctId":718,"briefTitle":719,"status":188,"phases":720,"primaryCompletion":721,"completion":722,"start":723,"enrollment":102,"conditions":724,"interventions":728},"NCT07578558","NAI for Sepsis With Persistent Lymphopenia",[86],"2027-08-03","2027-10-04","2026-07-06",[28,725,30,726,727],"Septic Shock","Immunosuppression","Critical Illness",[694],{"trials":730,"activeCount":12},[731],{"nctId":732,"briefTitle":733,"status":201,"phases":734,"primaryCompletion":735,"completion":163,"start":736,"enrollment":12,"conditions":737,"interventions":741},"NCT07492875","Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia",[87],"2029-04-15","2026-04-15",[738,739,28,30,740],"Community-Acquired Pneumonia (CAP)","Acute Respiratory Distress Syndrome (ARDS)","Immunoparalysis",[694,742],"agenT-797",{"trials":744,"activeCount":12},[],{"trials":746,"activeCount":12},[],{"intervention":153,"totalTrials":748,"cells":749},24,{"EARLY_PHASE1":750,"PHASE1":752,"PHASE2":764,"PHASE3":882,"PHASE4":884,"NA":886},{"trials":751,"activeCount":12},[],{"trials":753,"activeCount":113,"soonestReadout":48},[754],{"nctId":46,"briefTitle":47,"status":161,"phases":755,"primaryCompletion":48,"completion":756,"start":757,"enrollment":193,"conditions":758,"interventions":760},[85],"2027-03-15","2025-08-22",[759],"Non Hodgkin's Lymphoma Refractory\u002FRelapsed",[49,761,153,762,763],"CD19t-haNK suspension","Fludarabine","Rituximab",{"trials":765,"activeCount":113,"soonestReadout":43},[766,776,780,784,788,792,796,808,812,816,820,824,828,832,836,840,849,858,862,866,870,874,878],{"nctId":767,"briefTitle":768,"status":201,"phases":769,"primaryCompletion":770,"completion":382,"start":771,"enrollment":12,"conditions":772,"interventions":775},"NCT03647423","QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.",[85,86],"2020-08-31","2018-08-31",[773,774],"Chordoma","Unresectable Malignant Neoplasm",[335,317,142,143,146,336,148,151,153],{"nctId":309,"briefTitle":310,"status":109,"phases":777,"primaryCompletion":312,"completion":313,"start":314,"enrollment":19,"conditions":778,"interventions":779},[85,86],[15],[139,317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":130,"briefTitle":131,"status":109,"phases":781,"primaryCompletion":133,"completion":134,"start":135,"enrollment":19,"conditions":782,"interventions":783},[85,86],[137],[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,44],{"nctId":325,"briefTitle":326,"status":109,"phases":785,"primaryCompletion":328,"completion":329,"start":330,"enrollment":33,"conditions":786,"interventions":787},[85,86],[332,333],[335,317,140,141,142,143,144,145,146,336,148,150,151,153,184,155,217,319,337],{"nctId":339,"briefTitle":340,"status":201,"phases":789,"primaryCompletion":342,"completion":343,"start":344,"enrollment":12,"conditions":790,"interventions":791},[86],[346],[77,217,139,317,140,141,142,143,144,145,146,336,148,170,150,153,184,155,319],{"nctId":173,"briefTitle":174,"status":109,"phases":793,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":794,"interventions":795},[85,86],[181],[139,44,140,142,143,144,145,146,147,183,149,150,152,153,184,155,156],{"nctId":797,"briefTitle":798,"status":201,"phases":799,"primaryCompletion":800,"completion":382,"start":383,"enrollment":12,"conditions":801,"interventions":803},"NCT03197584","QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy",[85,86],"2019-02",[802],"Ovarian Cancer",[148,170,150,153,423,804,155,805,806,319,317,141,142,143,144,146,807],"Fulvestrant","Paclitaxel","omega-3 acid ethyl esters","haNK®",{"nctId":353,"briefTitle":354,"status":109,"phases":809,"primaryCompletion":356,"completion":357,"start":358,"enrollment":16,"conditions":810,"interventions":811},[85,86],[15],[317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":41,"briefTitle":42,"status":99,"phases":813,"primaryCompletion":43,"completion":53,"start":213,"enrollment":214,"conditions":814,"interventions":815},[86],[15],[44,139,171,217,77,153,184,155,218],{"nctId":366,"briefTitle":367,"status":201,"phases":817,"primaryCompletion":344,"completion":369,"start":370,"enrollment":12,"conditions":818,"interventions":819},[86],[372],[217,152,374,153,140,142,143,144,146,375,148,317,336,294,376],{"nctId":378,"briefTitle":379,"status":201,"phases":821,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":822,"interventions":823},[85,86],[385],[183,149,387,388,389,374,390,391,392,393,317,140,141,142,143,144,145,146,336],{"nctId":220,"briefTitle":221,"status":201,"phases":825,"primaryCompletion":223,"completion":223,"start":224,"enrollment":12,"conditions":826,"interventions":827},[85,86],[226,227],[140,144,147,183,150,153,184,155,156,229,230,142,143,145,146,151,44],{"nctId":410,"briefTitle":411,"status":109,"phases":829,"primaryCompletion":133,"completion":413,"start":414,"enrollment":24,"conditions":830,"interventions":831},[85,86],[15],[139,317,140,141,142,143,144,145,146,147,149,150,153,154,155,156,319,148],{"nctId":418,"briefTitle":419,"status":201,"phases":833,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":834,"interventions":835},[85,86],[26],[148,170,150,152,153,423,155,156,424,317,142,143,146,336],{"nctId":426,"briefTitle":427,"status":201,"phases":837,"primaryCompletion":429,"completion":343,"start":430,"enrollment":12,"conditions":838,"interventions":839},[86],[432],[155,184,139,156,140,142,143,144,145,146,148,317,336,153,434,435],{"nctId":841,"briefTitle":842,"status":201,"phases":843,"primaryCompletion":381,"completion":382,"start":844,"enrollment":12,"conditions":845,"interventions":847},"NCT03169738","QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1\u002FPD-L1 Inhibitors",[85,86],"2018-02",[846],"Non-small Cell Lung Cancer",[183,170,150,152,389,184,390,391,848,443,393,319,317,140,141,142,143,144,145,146,336],"nab paclitaxel",{"nctId":850,"briefTitle":851,"status":201,"phases":852,"primaryCompletion":381,"completion":382,"start":344,"enrollment":12,"conditions":853,"interventions":855},"NCT03169777","QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC",[85,86],[854],"Colorectal Cancer",[183,149,387,856,153,184,390,391,848,443,393,857,317,140,141,142,143,144,145,146,336],"cetuximab","oxaliplatin",{"nctId":251,"briefTitle":252,"status":109,"phases":859,"primaryCompletion":254,"completion":255,"start":256,"enrollment":24,"conditions":860,"interventions":861},[85,86],[258],[44,171,260,153],{"nctId":437,"briefTitle":438,"status":201,"phases":863,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":864,"interventions":865},[85,86],[441],[148,170,150,151,152,389,184,390,391,392,443,393,317,140,141,142,143,144,145,146,336],{"nctId":445,"briefTitle":446,"status":201,"phases":867,"primaryCompletion":381,"completion":448,"start":383,"enrollment":12,"conditions":868,"interventions":869},[85,86],[450],[183,149,387,389,184,391,392,393,319,197,317,143,336],{"nctId":453,"briefTitle":454,"status":201,"phases":871,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":872,"interventions":873},[85,86],[181],[183,149,387,388,389,184,155,392,393,317,140,142,143,144,145,146,336],{"nctId":459,"briefTitle":460,"status":201,"phases":875,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":876,"interventions":877},[85,86],[463],[148,170,150,152,153,423,155,392,465,424,317,140,142,143,145,146,336],{"nctId":467,"briefTitle":468,"status":109,"phases":879,"primaryCompletion":470,"completion":357,"start":471,"enrollment":24,"conditions":880,"interventions":881},[85,86],[15],[153,319,150,184,155,392,149,183,317,474,140,144],{"trials":883,"activeCount":12},[],{"trials":885,"activeCount":12},[],{"trials":887,"activeCount":12},[],{"intervention":77,"totalTrials":271,"cells":889},{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":905,"PHASE3":923,"PHASE4":925,"NA":927},{"trials":891,"activeCount":12},[],{"trials":893,"activeCount":12},[894],{"nctId":895,"briefTitle":896,"status":119,"phases":897,"primaryCompletion":898,"completion":898,"start":899,"enrollment":707,"conditions":900,"interventions":902},"NCT02235688","Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors",[85],"2017-01","2014-08",[901],"Metastatic Solid Tumors",[903,903,903,904],"aldoxorubicin","gemcitabine",{"trials":906,"activeCount":33,"soonestReadout":43},[907,911,915,919],{"nctId":339,"briefTitle":340,"status":201,"phases":908,"primaryCompletion":342,"completion":343,"start":344,"enrollment":12,"conditions":909,"interventions":910},[86],[346],[77,217,139,317,140,141,142,143,144,145,146,336,148,170,150,153,184,155,319],{"nctId":41,"briefTitle":42,"status":99,"phases":912,"primaryCompletion":43,"completion":53,"start":213,"enrollment":214,"conditions":913,"interventions":914},[86],[15],[44,139,171,217,77,153,184,155,218],{"nctId":399,"briefTitle":400,"status":119,"phases":916,"primaryCompletion":402,"completion":402,"start":403,"enrollment":404,"conditions":917,"interventions":918},[85,86],[406],[408,77,217],{"nctId":74,"briefTitle":75,"status":161,"phases":920,"primaryCompletion":76,"completion":76,"start":233,"enrollment":193,"conditions":921,"interventions":922},[86],[235],[77,44,210],{"trials":924,"activeCount":12},[],{"trials":926,"activeCount":12},[],{"trials":928,"activeCount":12},[],{"intervention":171,"totalTrials":19,"cells":930},{"EARLY_PHASE1":931,"PHASE1":933,"PHASE2":947,"PHASE3":961,"PHASE4":963,"NA":965},{"trials":932,"activeCount":12},[],{"trials":934,"activeCount":12},[935],{"nctId":936,"briefTitle":937,"status":119,"phases":938,"primaryCompletion":939,"completion":940,"start":941,"enrollment":942,"conditions":943,"interventions":946},"NCT04050709","QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers",[85],"2021-03-30","2026-03-25","2019-07-18",16,[944,945,32],"Locally Advanced Solid Tumor","Metastatic Cancer",[171],{"trials":948,"activeCount":33,"soonestReadout":43},[949,953,957],{"nctId":159,"briefTitle":160,"status":161,"phases":950,"primaryCompletion":163,"completion":164,"start":165,"enrollment":166,"conditions":951,"interventions":952},[86],[168],[170,171,44],{"nctId":41,"briefTitle":42,"status":99,"phases":954,"primaryCompletion":43,"completion":53,"start":213,"enrollment":214,"conditions":955,"interventions":956},[86],[15],[44,139,171,217,77,153,184,155,218],{"nctId":251,"briefTitle":252,"status":109,"phases":958,"primaryCompletion":254,"completion":255,"start":256,"enrollment":24,"conditions":959,"interventions":960},[85,86],[258],[44,171,260,153],{"trials":962,"activeCount":12},[],{"trials":964,"activeCount":12},[],{"trials":966,"activeCount":12},[],{"intervention":197,"totalTrials":24,"cells":968},{"EARLY_PHASE1":969,"PHASE1":971,"PHASE2":977,"PHASE3":987,"PHASE4":989,"NA":991},{"trials":970,"activeCount":12},[],{"trials":972,"activeCount":113,"soonestReadout":48},[973],{"nctId":46,"briefTitle":47,"status":161,"phases":974,"primaryCompletion":48,"completion":756,"start":757,"enrollment":193,"conditions":975,"interventions":976},[85],[759],[49,761,153,762,763],{"trials":978,"activeCount":113,"soonestReadout":190},[979,983],{"nctId":186,"briefTitle":187,"status":188,"phases":980,"primaryCompletion":190,"completion":191,"start":192,"enrollment":193,"conditions":981,"interventions":982},[86],[195],[82,44,197],{"nctId":445,"briefTitle":446,"status":201,"phases":984,"primaryCompletion":381,"completion":448,"start":383,"enrollment":12,"conditions":985,"interventions":986},[85,86],[450],[183,149,387,389,184,391,392,393,319,197,317,143,336],{"trials":988,"activeCount":12},[],{"trials":990,"activeCount":12},[],{"trials":992,"activeCount":12},[],{"intervention":82,"totalTrials":33,"cells":994},{"EARLY_PHASE1":995,"PHASE1":997,"PHASE2":999,"PHASE3":1012,"PHASE4":1014,"NA":1016},{"trials":996,"activeCount":12},[],{"trials":998,"activeCount":12},[],{"trials":1000,"activeCount":33,"soonestReadout":81},[1001,1005],{"nctId":186,"briefTitle":187,"status":188,"phases":1002,"primaryCompletion":190,"completion":191,"start":192,"enrollment":193,"conditions":1003,"interventions":1004},[86],[195],[82,44,197],{"nctId":79,"briefTitle":80,"status":161,"phases":1006,"primaryCompletion":81,"completion":1007,"start":1008,"enrollment":193,"conditions":1009,"interventions":1011},[86],"2028-05-25","2025-11-11",[1010],"Relapsed B-Cell Non Hodgkin Lymphoma",[82],{"trials":1013,"activeCount":12},[],{"trials":1015,"activeCount":12},[],{"trials":1017,"activeCount":12},[],{"intervention":64,"totalTrials":33,"cells":1019},{"EARLY_PHASE1":1020,"PHASE1":1022,"PHASE2":1024,"PHASE3":1034,"PHASE4":1043,"NA":1045},{"trials":1021,"activeCount":12},[],{"trials":1023,"activeCount":12},[],{"trials":1025,"activeCount":113,"soonestReadout":63},[1026],{"nctId":61,"briefTitle":62,"status":99,"phases":1027,"primaryCompletion":63,"completion":1028,"start":1029,"enrollment":1030,"conditions":1031,"interventions":1033},[85,86],"2039-03-04","2014-07-21",369,[1032],"Non-muscle Invasive Bladder Cancer",[64,64],{"trials":1035,"activeCount":12},[1036],{"nctId":1037,"briefTitle":1038,"status":201,"phases":1039,"primaryCompletion":1040,"completion":1040,"start":48,"enrollment":12,"conditions":1041,"interventions":1042},"NCT07551544","ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve\u002FBCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer",[87],"2032-05",[23],[64,64],{"trials":1044,"activeCount":12},[],{"trials":1046,"activeCount":12},[],{"intervention":155,"totalTrials":193,"cells":1048},{"EARLY_PHASE1":1049,"PHASE1":1051,"PHASE2":1053,"PHASE3":1135,"PHASE4":1137,"NA":1139},{"trials":1050,"activeCount":12},[],{"trials":1052,"activeCount":12},[],{"trials":1054,"activeCount":113,"soonestReadout":43},[1055,1059,1063,1067,1071,1075,1079,1083,1087,1091,1095,1099,1103,1107,1111,1115,1119,1123,1127,1131],{"nctId":309,"briefTitle":310,"status":109,"phases":1056,"primaryCompletion":312,"completion":313,"start":314,"enrollment":19,"conditions":1057,"interventions":1058},[85,86],[15],[139,317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":130,"briefTitle":131,"status":109,"phases":1060,"primaryCompletion":133,"completion":134,"start":135,"enrollment":19,"conditions":1061,"interventions":1062},[85,86],[137],[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,44],{"nctId":325,"briefTitle":326,"status":109,"phases":1064,"primaryCompletion":328,"completion":329,"start":330,"enrollment":33,"conditions":1065,"interventions":1066},[85,86],[332,333],[335,317,140,141,142,143,144,145,146,336,148,150,151,153,184,155,217,319,337],{"nctId":339,"briefTitle":340,"status":201,"phases":1068,"primaryCompletion":342,"completion":343,"start":344,"enrollment":12,"conditions":1069,"interventions":1070},[86],[346],[77,217,139,317,140,141,142,143,144,145,146,336,148,170,150,153,184,155,319],{"nctId":173,"briefTitle":174,"status":109,"phases":1072,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":1073,"interventions":1074},[85,86],[181],[139,44,140,142,143,144,145,146,147,183,149,150,152,153,184,155,156],{"nctId":797,"briefTitle":798,"status":201,"phases":1076,"primaryCompletion":800,"completion":382,"start":383,"enrollment":12,"conditions":1077,"interventions":1078},[85,86],[802],[148,170,150,153,423,804,155,805,806,319,317,141,142,143,144,146,807],{"nctId":353,"briefTitle":354,"status":109,"phases":1080,"primaryCompletion":356,"completion":357,"start":358,"enrollment":16,"conditions":1081,"interventions":1082},[85,86],[15],[317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":41,"briefTitle":42,"status":99,"phases":1084,"primaryCompletion":43,"completion":53,"start":213,"enrollment":214,"conditions":1085,"interventions":1086},[86],[15],[44,139,171,217,77,153,184,155,218],{"nctId":378,"briefTitle":379,"status":201,"phases":1088,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":1089,"interventions":1090},[85,86],[385],[183,149,387,388,389,374,390,391,392,393,317,140,141,142,143,144,145,146,336],{"nctId":220,"briefTitle":221,"status":201,"phases":1092,"primaryCompletion":223,"completion":223,"start":224,"enrollment":12,"conditions":1093,"interventions":1094},[85,86],[226,227],[140,144,147,183,150,153,184,155,156,229,230,142,143,145,146,151,44],{"nctId":410,"briefTitle":411,"status":109,"phases":1096,"primaryCompletion":133,"completion":413,"start":414,"enrollment":24,"conditions":1097,"interventions":1098},[85,86],[15],[139,317,140,141,142,143,144,145,146,147,149,150,153,154,155,156,319,148],{"nctId":418,"briefTitle":419,"status":201,"phases":1100,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":1101,"interventions":1102},[85,86],[26],[148,170,150,152,153,423,155,156,424,317,142,143,146,336],{"nctId":426,"briefTitle":427,"status":201,"phases":1104,"primaryCompletion":429,"completion":343,"start":430,"enrollment":12,"conditions":1105,"interventions":1106},[86],[432],[155,184,139,156,140,142,143,144,145,146,148,317,336,153,434,435],{"nctId":841,"briefTitle":842,"status":201,"phases":1108,"primaryCompletion":381,"completion":382,"start":844,"enrollment":12,"conditions":1109,"interventions":1110},[85,86],[846],[183,170,150,152,389,184,390,391,848,443,393,319,317,140,141,142,143,144,145,146,336],{"nctId":850,"briefTitle":851,"status":201,"phases":1112,"primaryCompletion":381,"completion":382,"start":344,"enrollment":12,"conditions":1113,"interventions":1114},[85,86],[854],[183,149,387,856,153,184,390,391,848,443,393,857,317,140,141,142,143,144,145,146,336],{"nctId":437,"briefTitle":438,"status":201,"phases":1116,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":1117,"interventions":1118},[85,86],[441],[148,170,150,151,152,389,184,390,391,392,443,393,317,140,141,142,143,144,145,146,336],{"nctId":445,"briefTitle":446,"status":201,"phases":1120,"primaryCompletion":381,"completion":448,"start":383,"enrollment":12,"conditions":1121,"interventions":1122},[85,86],[450],[183,149,387,389,184,391,392,393,319,197,317,143,336],{"nctId":453,"briefTitle":454,"status":201,"phases":1124,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":1125,"interventions":1126},[85,86],[181],[183,149,387,388,389,184,155,392,393,317,140,142,143,144,145,146,336],{"nctId":459,"briefTitle":460,"status":201,"phases":1128,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":1129,"interventions":1130},[85,86],[463],[148,170,150,152,153,423,155,392,465,424,317,140,142,143,145,146,336],{"nctId":467,"briefTitle":468,"status":109,"phases":1132,"primaryCompletion":470,"completion":357,"start":471,"enrollment":24,"conditions":1133,"interventions":1134},[85,86],[15],[153,319,150,184,155,392,149,183,317,474,140,144],{"trials":1136,"activeCount":12},[],{"trials":1138,"activeCount":12},[],{"trials":1140,"activeCount":12},[],{"intervention":149,"totalTrials":92,"cells":1142},{"EARLY_PHASE1":1143,"PHASE1":1145,"PHASE2":1147,"PHASE3":1217,"PHASE4":1219,"NA":1221},{"trials":1144,"activeCount":12},[],{"trials":1146,"activeCount":12},[],{"trials":1148,"activeCount":113,"soonestReadout":163},[1149,1153,1157,1161,1165,1169,1173,1177,1181,1185,1189,1193,1197,1201,1205,1209,1213],{"nctId":309,"briefTitle":310,"status":109,"phases":1150,"primaryCompletion":312,"completion":313,"start":314,"enrollment":19,"conditions":1151,"interventions":1152},[85,86],[15],[139,317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":130,"briefTitle":131,"status":109,"phases":1154,"primaryCompletion":133,"completion":134,"start":135,"enrollment":19,"conditions":1155,"interventions":1156},[85,86],[137],[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,44],{"nctId":339,"briefTitle":340,"status":201,"phases":1158,"primaryCompletion":342,"completion":343,"start":344,"enrollment":12,"conditions":1159,"interventions":1160},[86],[346],[77,217,139,317,140,141,142,143,144,145,146,336,148,170,150,153,184,155,319],{"nctId":159,"briefTitle":160,"status":161,"phases":1162,"primaryCompletion":163,"completion":164,"start":165,"enrollment":166,"conditions":1163,"interventions":1164},[86],[168],[170,171,44],{"nctId":173,"briefTitle":174,"status":109,"phases":1166,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":1167,"interventions":1168},[85,86],[181],[139,44,140,142,143,144,145,146,147,183,149,150,152,153,184,155,156],{"nctId":797,"briefTitle":798,"status":201,"phases":1170,"primaryCompletion":800,"completion":382,"start":383,"enrollment":12,"conditions":1171,"interventions":1172},[85,86],[802],[148,170,150,153,423,804,155,805,806,319,317,141,142,143,144,146,807],{"nctId":353,"briefTitle":354,"status":109,"phases":1174,"primaryCompletion":356,"completion":357,"start":358,"enrollment":16,"conditions":1175,"interventions":1176},[85,86],[15],[317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":378,"briefTitle":379,"status":201,"phases":1178,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":1179,"interventions":1180},[85,86],[385],[183,149,387,388,389,374,390,391,392,393,317,140,141,142,143,144,145,146,336],{"nctId":410,"briefTitle":411,"status":109,"phases":1182,"primaryCompletion":133,"completion":413,"start":414,"enrollment":24,"conditions":1183,"interventions":1184},[85,86],[15],[139,317,140,141,142,143,144,145,146,147,149,150,153,154,155,156,319,148],{"nctId":418,"briefTitle":419,"status":201,"phases":1186,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":1187,"interventions":1188},[85,86],[26],[148,170,150,152,153,423,155,156,424,317,142,143,146,336],{"nctId":841,"briefTitle":842,"status":201,"phases":1190,"primaryCompletion":381,"completion":382,"start":844,"enrollment":12,"conditions":1191,"interventions":1192},[85,86],[846],[183,170,150,152,389,184,390,391,848,443,393,319,317,140,141,142,143,144,145,146,336],{"nctId":850,"briefTitle":851,"status":201,"phases":1194,"primaryCompletion":381,"completion":382,"start":344,"enrollment":12,"conditions":1195,"interventions":1196},[85,86],[854],[183,149,387,856,153,184,390,391,848,443,393,857,317,140,141,142,143,144,145,146,336],{"nctId":437,"briefTitle":438,"status":201,"phases":1198,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":1199,"interventions":1200},[85,86],[441],[148,170,150,151,152,389,184,390,391,392,443,393,317,140,141,142,143,144,145,146,336],{"nctId":445,"briefTitle":446,"status":201,"phases":1202,"primaryCompletion":381,"completion":448,"start":383,"enrollment":12,"conditions":1203,"interventions":1204},[85,86],[450],[183,149,387,389,184,391,392,393,319,197,317,143,336],{"nctId":453,"briefTitle":454,"status":201,"phases":1206,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":1207,"interventions":1208},[85,86],[181],[183,149,387,388,389,184,155,392,393,317,140,142,143,144,145,146,336],{"nctId":459,"briefTitle":460,"status":201,"phases":1210,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":1211,"interventions":1212},[85,86],[463],[148,170,150,152,153,423,155,392,465,424,317,140,142,143,145,146,336],{"nctId":467,"briefTitle":468,"status":109,"phases":1214,"primaryCompletion":470,"completion":357,"start":471,"enrollment":24,"conditions":1215,"interventions":1216},[85,86],[15],[153,319,150,184,155,392,149,183,317,474,140,144],{"trials":1218,"activeCount":12},[],{"trials":1220,"activeCount":12},[],{"trials":1222,"activeCount":12},[],{"intervention":184,"totalTrials":1224,"cells":1225},15,{"EARLY_PHASE1":1226,"PHASE1":1228,"PHASE2":1230,"PHASE3":1292,"PHASE4":1294,"NA":1296},{"trials":1227,"activeCount":12},[],{"trials":1229,"activeCount":12},[],{"trials":1231,"activeCount":113,"soonestReadout":43},[1232,1236,1240,1244,1248,1252,1256,1260,1264,1268,1272,1276,1280,1284,1288],{"nctId":325,"briefTitle":326,"status":109,"phases":1233,"primaryCompletion":328,"completion":329,"start":330,"enrollment":33,"conditions":1234,"interventions":1235},[85,86],[332,333],[335,317,140,141,142,143,144,145,146,336,148,150,151,153,184,155,217,319,337],{"nctId":339,"briefTitle":340,"status":201,"phases":1237,"primaryCompletion":342,"completion":343,"start":344,"enrollment":12,"conditions":1238,"interventions":1239},[86],[346],[77,217,139,317,140,141,142,143,144,145,146,336,148,170,150,153,184,155,319],{"nctId":173,"briefTitle":174,"status":109,"phases":1241,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":1242,"interventions":1243},[85,86],[181],[139,44,140,142,143,144,145,146,147,183,149,150,152,153,184,155,156],{"nctId":797,"briefTitle":798,"status":201,"phases":1245,"primaryCompletion":800,"completion":382,"start":383,"enrollment":12,"conditions":1246,"interventions":1247},[85,86],[802],[148,170,150,153,423,804,155,805,806,319,317,141,142,143,144,146,807],{"nctId":41,"briefTitle":42,"status":99,"phases":1249,"primaryCompletion":43,"completion":53,"start":213,"enrollment":214,"conditions":1250,"interventions":1251},[86],[15],[44,139,171,217,77,153,184,155,218],{"nctId":220,"briefTitle":221,"status":201,"phases":1253,"primaryCompletion":223,"completion":223,"start":224,"enrollment":12,"conditions":1254,"interventions":1255},[85,86],[226,227],[140,144,147,183,150,153,184,155,156,229,230,142,143,145,146,151,44],{"nctId":418,"briefTitle":419,"status":201,"phases":1257,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":1258,"interventions":1259},[85,86],[26],[148,170,150,152,153,423,155,156,424,317,142,143,146,336],{"nctId":426,"briefTitle":427,"status":201,"phases":1261,"primaryCompletion":429,"completion":343,"start":430,"enrollment":12,"conditions":1262,"interventions":1263},[86],[432],[155,184,139,156,140,142,143,144,145,146,148,317,336,153,434,435],{"nctId":841,"briefTitle":842,"status":201,"phases":1265,"primaryCompletion":381,"completion":382,"start":844,"enrollment":12,"conditions":1266,"interventions":1267},[85,86],[846],[183,170,150,152,389,184,390,391,848,443,393,319,317,140,141,142,143,144,145,146,336],{"nctId":850,"briefTitle":851,"status":201,"phases":1269,"primaryCompletion":381,"completion":382,"start":344,"enrollment":12,"conditions":1270,"interventions":1271},[85,86],[854],[183,149,387,856,153,184,390,391,848,443,393,857,317,140,141,142,143,144,145,146,336],{"nctId":437,"briefTitle":438,"status":201,"phases":1273,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":1274,"interventions":1275},[85,86],[441],[148,170,150,151,152,389,184,390,391,392,443,393,317,140,141,142,143,144,145,146,336],{"nctId":445,"briefTitle":446,"status":201,"phases":1277,"primaryCompletion":381,"completion":448,"start":383,"enrollment":12,"conditions":1278,"interventions":1279},[85,86],[450],[183,149,387,389,184,391,392,393,319,197,317,143,336],{"nctId":453,"briefTitle":454,"status":201,"phases":1281,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":1282,"interventions":1283},[85,86],[181],[183,149,387,388,389,184,155,392,393,317,140,142,143,144,145,146,336],{"nctId":459,"briefTitle":460,"status":201,"phases":1285,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":1286,"interventions":1287},[85,86],[463],[148,170,150,152,153,423,155,392,465,424,317,140,142,143,145,146,336],{"nctId":467,"briefTitle":468,"status":109,"phases":1289,"primaryCompletion":470,"completion":357,"start":471,"enrollment":24,"conditions":1290,"interventions":1291},[85,86],[15],[153,319,150,184,155,392,149,183,317,474,140,144],{"trials":1293,"activeCount":12},[],{"trials":1295,"activeCount":12},[],{"trials":1297,"activeCount":12},[],{"intervention":139,"totalTrials":1299,"cells":1300},7,{"EARLY_PHASE1":1301,"PHASE1":1303,"PHASE2":1305,"PHASE3":1335,"PHASE4":1337,"NA":1339},{"trials":1302,"activeCount":12},[],{"trials":1304,"activeCount":12},[],{"trials":1306,"activeCount":113,"soonestReadout":43},[1307,1311,1315,1319,1323,1327,1331],{"nctId":309,"briefTitle":310,"status":109,"phases":1308,"primaryCompletion":312,"completion":313,"start":314,"enrollment":19,"conditions":1309,"interventions":1310},[85,86],[15],[139,317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":130,"briefTitle":131,"status":109,"phases":1312,"primaryCompletion":133,"completion":134,"start":135,"enrollment":19,"conditions":1313,"interventions":1314},[85,86],[137],[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,44],{"nctId":339,"briefTitle":340,"status":201,"phases":1316,"primaryCompletion":342,"completion":343,"start":344,"enrollment":12,"conditions":1317,"interventions":1318},[86],[346],[77,217,139,317,140,141,142,143,144,145,146,336,148,170,150,153,184,155,319],{"nctId":173,"briefTitle":174,"status":109,"phases":1320,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":1321,"interventions":1322},[85,86],[181],[139,44,140,142,143,144,145,146,147,183,149,150,152,153,184,155,156],{"nctId":41,"briefTitle":42,"status":99,"phases":1324,"primaryCompletion":43,"completion":53,"start":213,"enrollment":214,"conditions":1325,"interventions":1326},[86],[15],[44,139,171,217,77,153,184,155,218],{"nctId":410,"briefTitle":411,"status":109,"phases":1328,"primaryCompletion":133,"completion":413,"start":414,"enrollment":24,"conditions":1329,"interventions":1330},[85,86],[15],[139,317,140,141,142,143,144,145,146,147,149,150,153,154,155,156,319,148],{"nctId":426,"briefTitle":427,"status":201,"phases":1332,"primaryCompletion":429,"completion":343,"start":430,"enrollment":12,"conditions":1333,"interventions":1334},[86],[432],[155,184,139,156,140,142,143,144,145,146,148,317,336,153,434,435],{"trials":1336,"activeCount":12},[],{"trials":1338,"activeCount":12},[],{"trials":1340,"activeCount":12},[],{"intervention":210,"totalTrials":24,"cells":1342},{"EARLY_PHASE1":1343,"PHASE1":1345,"PHASE2":1347,"PHASE3":1361,"PHASE4":1363,"NA":1365},{"trials":1344,"activeCount":12},[],{"trials":1346,"activeCount":12},[],{"trials":1348,"activeCount":113,"soonestReadout":76},[1349,1353,1357],{"nctId":199,"briefTitle":200,"status":201,"phases":1350,"primaryCompletion":203,"completion":204,"start":205,"enrollment":12,"conditions":1351,"interventions":1352},[86],[207],[44,209,210],{"nctId":74,"briefTitle":75,"status":161,"phases":1354,"primaryCompletion":76,"completion":76,"start":233,"enrollment":193,"conditions":1355,"interventions":1356},[86],[235],[77,44,210],{"nctId":238,"briefTitle":239,"status":201,"phases":1358,"primaryCompletion":203,"completion":204,"start":241,"enrollment":12,"conditions":1359,"interventions":1360},[86],[207],[44,209,210],{"trials":1362,"activeCount":12},[],{"trials":1364,"activeCount":12},[],{"trials":1366,"activeCount":12},[],{"intervention":513,"totalTrials":113,"cells":1368},{"EARLY_PHASE1":1369,"PHASE1":1371,"PHASE2":1373,"PHASE3":1379,"PHASE4":1381,"NA":1383},{"trials":1370,"activeCount":12},[],{"trials":1372,"activeCount":12},[],{"trials":1374,"activeCount":113,"soonestReadout":72},[1375],{"nctId":70,"briefTitle":71,"status":188,"phases":1376,"primaryCompletion":72,"completion":508,"start":509,"enrollment":193,"conditions":1377,"interventions":1378},[86],[511],[39,513],{"trials":1380,"activeCount":12},[],{"trials":1382,"activeCount":12},[],{"trials":1384,"activeCount":12},[],{"intervention":218,"totalTrials":113,"cells":1386},{"EARLY_PHASE1":1387,"PHASE1":1389,"PHASE2":1391,"PHASE3":1397,"PHASE4":1399,"NA":1401},{"trials":1388,"activeCount":12},[],{"trials":1390,"activeCount":12},[],{"trials":1392,"activeCount":113,"soonestReadout":43},[1393],{"nctId":41,"briefTitle":42,"status":99,"phases":1394,"primaryCompletion":43,"completion":53,"start":213,"enrollment":214,"conditions":1395,"interventions":1396},[86],[15],[44,139,171,217,77,153,184,155,218],{"trials":1398,"activeCount":12},[],{"trials":1400,"activeCount":12},[],{"trials":1402,"activeCount":12},[],{"intervention":1404,"totalTrials":113,"cells":1405},"N-803 + Pembrolizumab",{"EARLY_PHASE1":1406,"PHASE1":1408,"PHASE2":1410,"PHASE3":1440,"PHASE4":1442,"NA":1444},{"trials":1407,"activeCount":12},[],{"trials":1409,"activeCount":12},[],{"trials":1411,"activeCount":113,"soonestReadout":1416},[1412],{"nctId":1413,"briefTitle":1414,"status":99,"phases":1415,"primaryCompletion":1416,"completion":164,"start":1417,"enrollment":1418,"conditions":1419,"interventions":1428},"NCT03228667","QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors",[86],"2029-08-31","2018-12-11",40,[1420,1421,385,441,26,463,1422,1423,1424,1425,1426,1427,854],"Non-Small Cell Lung Cancer","Small Cell Lung Cancer","Renal Cell Carcinoma","Gastric Cancer","Cervical Cancer","Hepatocellular Carcinoma","Microsatellite Instability","Mismatch Repair Deficiency",[1404,1429,1430,1431,1432,1433,1434,1435,1436,1437,1438,1439],"N-803 + Nivolumab","N-803 + Atezolizumab","N-803 + Avelumab","N-803 + Durvalumab","N-803 + Pembrolizumab + PD-L1 t-haNK","N-803 + Nivolumab + PD-L1 t-haNK","N-803 + Atezolizumab + PD-L1 t-haNK","N-803 + Avelumab + PD-L1 t-haNK","N-803 + Durvalumab + PD-L1 t-haNK","N-803 + Docetaxel + Pembrolizumab","N-803 + Docetaxel + Nivolumab",{"trials":1441,"activeCount":12},[],{"trials":1443,"activeCount":12},[],{"trials":1445,"activeCount":12},[],{"intervention":1429,"totalTrials":113,"cells":1447},{"EARLY_PHASE1":1448,"PHASE1":1450,"PHASE2":1452,"PHASE3":1458,"PHASE4":1460,"NA":1462},{"trials":1449,"activeCount":12},[],{"trials":1451,"activeCount":12},[],{"trials":1453,"activeCount":113,"soonestReadout":1416},[1454],{"nctId":1413,"briefTitle":1414,"status":99,"phases":1455,"primaryCompletion":1416,"completion":164,"start":1417,"enrollment":1418,"conditions":1456,"interventions":1457},[86],[1420,1421,385,441,26,463,1422,1423,1424,1425,1426,1427,854],[1404,1429,1430,1431,1432,1433,1434,1435,1436,1437,1438,1439],{"trials":1459,"activeCount":12},[],{"trials":1461,"activeCount":12},[],{"trials":1463,"activeCount":12},[],{"intervention":1430,"totalTrials":113,"cells":1465},{"EARLY_PHASE1":1466,"PHASE1":1468,"PHASE2":1470,"PHASE3":1476,"PHASE4":1478,"NA":1480},{"trials":1467,"activeCount":12},[],{"trials":1469,"activeCount":12},[],{"trials":1471,"activeCount":113,"soonestReadout":1416},[1472],{"nctId":1413,"briefTitle":1414,"status":99,"phases":1473,"primaryCompletion":1416,"completion":164,"start":1417,"enrollment":1418,"conditions":1474,"interventions":1475},[86],[1420,1421,385,441,26,463,1422,1423,1424,1425,1426,1427,854],[1404,1429,1430,1431,1432,1433,1434,1435,1436,1437,1438,1439],{"trials":1477,"activeCount":12},[],{"trials":1479,"activeCount":12},[],{"trials":1481,"activeCount":12},[],{"intervention":1431,"totalTrials":113,"cells":1483},{"EARLY_PHASE1":1484,"PHASE1":1486,"PHASE2":1488,"PHASE3":1494,"PHASE4":1496,"NA":1498},{"trials":1485,"activeCount":12},[],{"trials":1487,"activeCount":12},[],{"trials":1489,"activeCount":113,"soonestReadout":1416},[1490],{"nctId":1413,"briefTitle":1414,"status":99,"phases":1491,"primaryCompletion":1416,"completion":164,"start":1417,"enrollment":1418,"conditions":1492,"interventions":1493},[86],[1420,1421,385,441,26,463,1422,1423,1424,1425,1426,1427,854],[1404,1429,1430,1431,1432,1433,1434,1435,1436,1437,1438,1439],{"trials":1495,"activeCount":12},[],{"trials":1497,"activeCount":12},[],{"trials":1499,"activeCount":12},[],{"intervention":1432,"totalTrials":113,"cells":1501},{"EARLY_PHASE1":1502,"PHASE1":1504,"PHASE2":1506,"PHASE3":1512,"PHASE4":1514,"NA":1516},{"trials":1503,"activeCount":12},[],{"trials":1505,"activeCount":12},[],{"trials":1507,"activeCount":113,"soonestReadout":1416},[1508],{"nctId":1413,"briefTitle":1414,"status":99,"phases":1509,"primaryCompletion":1416,"completion":164,"start":1417,"enrollment":1418,"conditions":1510,"interventions":1511},[86],[1420,1421,385,441,26,463,1422,1423,1424,1425,1426,1427,854],[1404,1429,1430,1431,1432,1433,1434,1435,1436,1437,1438,1439],{"trials":1513,"activeCount":12},[],{"trials":1515,"activeCount":12},[],{"trials":1517,"activeCount":12},[],{"intervention":1433,"totalTrials":113,"cells":1519},{"EARLY_PHASE1":1520,"PHASE1":1522,"PHASE2":1524,"PHASE3":1530,"PHASE4":1532,"NA":1534},{"trials":1521,"activeCount":12},[],{"trials":1523,"activeCount":12},[],{"trials":1525,"activeCount":113,"soonestReadout":1416},[1526],{"nctId":1413,"briefTitle":1414,"status":99,"phases":1527,"primaryCompletion":1416,"completion":164,"start":1417,"enrollment":1418,"conditions":1528,"interventions":1529},[86],[1420,1421,385,441,26,463,1422,1423,1424,1425,1426,1427,854],[1404,1429,1430,1431,1432,1433,1434,1435,1436,1437,1438,1439],{"trials":1531,"activeCount":12},[],{"trials":1533,"activeCount":12},[],{"trials":1535,"activeCount":12},[],{"intervention":1434,"totalTrials":113,"cells":1537},{"EARLY_PHASE1":1538,"PHASE1":1540,"PHASE2":1542,"PHASE3":1548,"PHASE4":1550,"NA":1552},{"trials":1539,"activeCount":12},[],{"trials":1541,"activeCount":12},[],{"trials":1543,"activeCount":113,"soonestReadout":1416},[1544],{"nctId":1413,"briefTitle":1414,"status":99,"phases":1545,"primaryCompletion":1416,"completion":164,"start":1417,"enrollment":1418,"conditions":1546,"interventions":1547},[86],[1420,1421,385,441,26,463,1422,1423,1424,1425,1426,1427,854],[1404,1429,1430,1431,1432,1433,1434,1435,1436,1437,1438,1439],{"trials":1549,"activeCount":12},[],{"trials":1551,"activeCount":12},[],{"trials":1553,"activeCount":12},[],{"intervention":1435,"totalTrials":113,"cells":1555},{"EARLY_PHASE1":1556,"PHASE1":1558,"PHASE2":1560,"PHASE3":1566,"PHASE4":1568,"NA":1570},{"trials":1557,"activeCount":12},[],{"trials":1559,"activeCount":12},[],{"trials":1561,"activeCount":113,"soonestReadout":1416},[1562],{"nctId":1413,"briefTitle":1414,"status":99,"phases":1563,"primaryCompletion":1416,"completion":164,"start":1417,"enrollment":1418,"conditions":1564,"interventions":1565},[86],[1420,1421,385,441,26,463,1422,1423,1424,1425,1426,1427,854],[1404,1429,1430,1431,1432,1433,1434,1435,1436,1437,1438,1439],{"trials":1567,"activeCount":12},[],{"trials":1569,"activeCount":12},[],{"trials":1571,"activeCount":12},[],{"intervention":1436,"totalTrials":113,"cells":1573},{"EARLY_PHASE1":1574,"PHASE1":1576,"PHASE2":1578,"PHASE3":1584,"PHASE4":1586,"NA":1588},{"trials":1575,"activeCount":12},[],{"trials":1577,"activeCount":12},[],{"trials":1579,"activeCount":113,"soonestReadout":1416},[1580],{"nctId":1413,"briefTitle":1414,"status":99,"phases":1581,"primaryCompletion":1416,"completion":164,"start":1417,"enrollment":1418,"conditions":1582,"interventions":1583},[86],[1420,1421,385,441,26,463,1422,1423,1424,1425,1426,1427,854],[1404,1429,1430,1431,1432,1433,1434,1435,1436,1437,1438,1439],{"trials":1585,"activeCount":12},[],{"trials":1587,"activeCount":12},[],{"trials":1589,"activeCount":12},[],{"intervention":1437,"totalTrials":113,"cells":1591},{"EARLY_PHASE1":1592,"PHASE1":1594,"PHASE2":1596,"PHASE3":1602,"PHASE4":1604,"NA":1606},{"trials":1593,"activeCount":12},[],{"trials":1595,"activeCount":12},[],{"trials":1597,"activeCount":113,"soonestReadout":1416},[1598],{"nctId":1413,"briefTitle":1414,"status":99,"phases":1599,"primaryCompletion":1416,"completion":164,"start":1417,"enrollment":1418,"conditions":1600,"interventions":1601},[86],[1420,1421,385,441,26,463,1422,1423,1424,1425,1426,1427,854],[1404,1429,1430,1431,1432,1433,1434,1435,1436,1437,1438,1439],{"trials":1603,"activeCount":12},[],{"trials":1605,"activeCount":12},[],{"trials":1607,"activeCount":12},[],{"intervention":1438,"totalTrials":113,"cells":1609},{"EARLY_PHASE1":1610,"PHASE1":1612,"PHASE2":1614,"PHASE3":1620,"PHASE4":1622,"NA":1624},{"trials":1611,"activeCount":12},[],{"trials":1613,"activeCount":12},[],{"trials":1615,"activeCount":113,"soonestReadout":1416},[1616],{"nctId":1413,"briefTitle":1414,"status":99,"phases":1617,"primaryCompletion":1416,"completion":164,"start":1417,"enrollment":1418,"conditions":1618,"interventions":1619},[86],[1420,1421,385,441,26,463,1422,1423,1424,1425,1426,1427,854],[1404,1429,1430,1431,1432,1433,1434,1435,1436,1437,1438,1439],{"trials":1621,"activeCount":12},[],{"trials":1623,"activeCount":12},[],{"trials":1625,"activeCount":12},[],{"intervention":1439,"totalTrials":113,"cells":1627},{"EARLY_PHASE1":1628,"PHASE1":1630,"PHASE2":1632,"PHASE3":1638,"PHASE4":1640,"NA":1642},{"trials":1629,"activeCount":12},[],{"trials":1631,"activeCount":12},[],{"trials":1633,"activeCount":113,"soonestReadout":1416},[1634],{"nctId":1413,"briefTitle":1414,"status":99,"phases":1635,"primaryCompletion":1416,"completion":164,"start":1417,"enrollment":1418,"conditions":1636,"interventions":1637},[86],[1420,1421,385,441,26,463,1422,1423,1424,1425,1426,1427,854],[1404,1429,1430,1431,1432,1433,1434,1435,1436,1437,1438,1439],{"trials":1639,"activeCount":12},[],{"trials":1641,"activeCount":12},[],{"trials":1643,"activeCount":12},[],{"intervention":1645,"totalTrials":113,"cells":1646},"Intravesical Recombinant Mycobacterium",{"EARLY_PHASE1":1647,"PHASE1":1649,"PHASE2":1651,"PHASE3":1661,"PHASE4":1663,"NA":1665},{"trials":1648,"activeCount":12},[],{"trials":1650,"activeCount":12},[],{"trials":1652,"activeCount":113,"soonestReadout":1657},[1653],{"nctId":1654,"briefTitle":1655,"status":161,"phases":1656,"primaryCompletion":1657,"completion":1657,"start":1658,"enrollment":1418,"conditions":1659,"interventions":1660},"NCT06800963","ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG",[85,86],"2028-02","2025-10-15",[23],[1645],{"trials":1662,"activeCount":12},[],{"trials":1664,"activeCount":12},[],{"trials":1666,"activeCount":12},[],{"intervention":59,"totalTrials":113,"cells":1668},{"EARLY_PHASE1":1669,"PHASE1":1671,"PHASE2":1673,"PHASE3":1682,"PHASE4":1684,"NA":1686},{"trials":1670,"activeCount":12},[],{"trials":1672,"activeCount":12},[],{"trials":1674,"activeCount":113,"soonestReadout":58},[1675],{"nctId":56,"briefTitle":57,"status":161,"phases":1676,"primaryCompletion":58,"completion":58,"start":1677,"enrollment":1418,"conditions":1678,"interventions":1681},[86],"2025-09-04",[248,1679,1680],"Long COVID Syndrome","Long Covid 19",[59],{"trials":1683,"activeCount":12},[],{"trials":1685,"activeCount":12},[],{"trials":1687,"activeCount":12},[],{"intervention":1689,"totalTrials":24,"cells":1690},"CD19 t-haNK",{"EARLY_PHASE1":1691,"PHASE1":1693,"PHASE2":1726,"PHASE3":1728,"PHASE4":1730,"NA":1732},{"trials":1692,"activeCount":12},[],{"trials":1694,"activeCount":33,"soonestReadout":1712},[1695,1708,1717],{"nctId":1696,"briefTitle":1697,"status":201,"phases":1698,"primaryCompletion":1699,"completion":1700,"start":1701,"enrollment":12,"conditions":1702,"interventions":1707},"NCT04052061","QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma",[85],"2021-09-18","2022-08-19","2019-09-16",[1703,1704,1705,1706],"Diffuse Large B Cell Lymphoma","Large-cell Lymphoma","Lymphoma, B-Cell","Lymphoma",[1689],{"nctId":1709,"briefTitle":1710,"status":161,"phases":1711,"primaryCompletion":1712,"completion":1712,"start":1713,"enrollment":123,"conditions":1714,"interventions":1716},"NCT06334991","Study for Subjects With Relapsed\u002FRefractory Non-Hodgkin Lymphoma",[85],"2028-03","2024-08-23",[1715],"Non-Hodgkin Lymphoma Refractory\u002F Relapsed",[1689],{"nctId":1718,"briefTitle":1719,"status":161,"phases":1720,"primaryCompletion":191,"completion":191,"start":1721,"enrollment":123,"conditions":1722,"interventions":1725},"NCT07556757","A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia",[85],"2025-04-11",[1723,1724],"B-ALL","Leukemia",[1689],{"trials":1727,"activeCount":12},[],{"trials":1729,"activeCount":12},[],{"trials":1731,"activeCount":12},[],{"trials":1733,"activeCount":12},[],{"intervention":1735,"totalTrials":113,"cells":1736},"IBRX-042",{"EARLY_PHASE1":1737,"PHASE1":1739,"PHASE2":1752,"PHASE3":1754,"PHASE4":1756,"NA":1758},{"trials":1738,"activeCount":12},[],{"trials":1740,"activeCount":113,"soonestReadout":1745},[1741],{"nctId":1742,"briefTitle":1743,"status":99,"phases":1744,"primaryCompletion":1745,"completion":1746,"start":1747,"enrollment":1748,"conditions":1749,"interventions":1751},"NCT05976828","IBRX-042 In Participants With HPV-Associated Tumors",[85],"2027-09-02","2033-08-14","2024-06-14",12,[1750],"HPV-Related Carcinoma",[1735],{"trials":1753,"activeCount":12},[],{"trials":1755,"activeCount":12},[],{"trials":1757,"activeCount":12},[],{"trials":1759,"activeCount":12},[],{"intervention":712,"totalTrials":113,"cells":1761},{"EARLY_PHASE1":1762,"PHASE1":1764,"PHASE2":1770,"PHASE3":1772,"PHASE4":1774,"NA":1776},{"trials":1763,"activeCount":12},[],{"trials":1765,"activeCount":113,"soonestReadout":704},[1766],{"nctId":701,"briefTitle":702,"status":188,"phases":1767,"primaryCompletion":704,"completion":705,"start":706,"enrollment":707,"conditions":1768,"interventions":1769},[85],[709,15],[711,712,713,714],{"trials":1771,"activeCount":12},[],{"trials":1773,"activeCount":12},[],{"trials":1775,"activeCount":12},[],{"trials":1777,"activeCount":12},[],{"intervention":713,"totalTrials":113,"cells":1779},{"EARLY_PHASE1":1780,"PHASE1":1782,"PHASE2":1788,"PHASE3":1790,"PHASE4":1792,"NA":1794},{"trials":1781,"activeCount":12},[],{"trials":1783,"activeCount":113,"soonestReadout":704},[1784],{"nctId":701,"briefTitle":702,"status":188,"phases":1785,"primaryCompletion":704,"completion":705,"start":706,"enrollment":707,"conditions":1786,"interventions":1787},[85],[709,15],[711,712,713,714],{"trials":1789,"activeCount":12},[],{"trials":1791,"activeCount":12},[],{"trials":1793,"activeCount":12},[],{"trials":1795,"activeCount":12},[],{"intervention":714,"totalTrials":113,"cells":1797},{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1806,"PHASE3":1808,"PHASE4":1810,"NA":1812},{"trials":1799,"activeCount":12},[],{"trials":1801,"activeCount":113,"soonestReadout":704},[1802],{"nctId":701,"briefTitle":702,"status":188,"phases":1803,"primaryCompletion":704,"completion":705,"start":706,"enrollment":707,"conditions":1804,"interventions":1805},[85],[709,15],[711,712,713,714],{"trials":1807,"activeCount":12},[],{"trials":1809,"activeCount":12},[],{"trials":1811,"activeCount":12},[],{"trials":1813,"activeCount":12},[],{"intervention":54,"totalTrials":113,"cells":1815},{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1824,"PHASE3":1826,"PHASE4":1828,"NA":1830},{"trials":1817,"activeCount":12},[],{"trials":1819,"activeCount":113,"soonestReadout":53},[1820],{"nctId":51,"briefTitle":52,"status":99,"phases":1821,"primaryCompletion":53,"completion":53,"start":101,"enrollment":102,"conditions":1822,"interventions":1823},[85],[104],[54,44],{"trials":1825,"activeCount":12},[],{"trials":1827,"activeCount":12},[],{"trials":1829,"activeCount":12},[],{"trials":1831,"activeCount":12},[],{"intervention":49,"totalTrials":113,"cells":1833},{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1842,"PHASE3":1844,"PHASE4":1846,"NA":1848},{"trials":1835,"activeCount":12},[],{"trials":1837,"activeCount":113,"soonestReadout":48},[1838],{"nctId":46,"briefTitle":47,"status":161,"phases":1839,"primaryCompletion":48,"completion":756,"start":757,"enrollment":193,"conditions":1840,"interventions":1841},[85],[759],[49,761,153,762,763],{"trials":1843,"activeCount":12},[],{"trials":1845,"activeCount":12},[],{"trials":1847,"activeCount":12},[],{"trials":1849,"activeCount":12},[],{"intervention":761,"totalTrials":113,"cells":1851},{"EARLY_PHASE1":1852,"PHASE1":1854,"PHASE2":1860,"PHASE3":1862,"PHASE4":1864,"NA":1866},{"trials":1853,"activeCount":12},[],{"trials":1855,"activeCount":113,"soonestReadout":48},[1856],{"nctId":46,"briefTitle":47,"status":161,"phases":1857,"primaryCompletion":48,"completion":756,"start":757,"enrollment":193,"conditions":1858,"interventions":1859},[85],[759],[49,761,153,762,763],{"trials":1861,"activeCount":12},[],{"trials":1863,"activeCount":12},[],{"trials":1865,"activeCount":12},[],{"trials":1867,"activeCount":12},[],{"intervention":762,"totalTrials":113,"cells":1869},{"EARLY_PHASE1":1870,"PHASE1":1872,"PHASE2":1878,"PHASE3":1880,"PHASE4":1882,"NA":1884},{"trials":1871,"activeCount":12},[],{"trials":1873,"activeCount":113,"soonestReadout":48},[1874],{"nctId":46,"briefTitle":47,"status":161,"phases":1875,"primaryCompletion":48,"completion":756,"start":757,"enrollment":193,"conditions":1876,"interventions":1877},[85],[759],[49,761,153,762,763],{"trials":1879,"activeCount":12},[],{"trials":1881,"activeCount":12},[],{"trials":1883,"activeCount":12},[],{"trials":1885,"activeCount":12},[],{"intervention":1887,"totalTrials":113,"cells":1888},"N803 plus Bacillus Calmette-Guerin",{"EARLY_PHASE1":1889,"PHASE1":1891,"PHASE2":1893,"PHASE3":1895,"PHASE4":1897,"NA":1899},{"trials":1890,"activeCount":12},[],{"trials":1892,"activeCount":12},[],{"trials":1894,"activeCount":12},[],{"trials":1896,"activeCount":12},[],{"trials":1898,"activeCount":12},[],{"trials":1900,"activeCount":113,"soonestReadout":1905},[1901],{"nctId":1902,"briefTitle":1903,"status":99,"phases":1904,"primaryCompletion":1905,"completion":1905,"start":1906,"enrollment":16,"conditions":1907,"interventions":1909},"NCT05981131","Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)",[],"2033-08-30","2023-08-17",[1908],"Non Muscle Invasive Bladder Cancer",[1887],{"intervention":903,"totalTrials":16,"cells":1911},{"EARLY_PHASE1":1912,"PHASE1":1914,"PHASE2":1939,"PHASE3":1956,"PHASE4":1969,"NA":1971},{"trials":1913,"activeCount":12},[],{"trials":1915,"activeCount":12},[1916,1920,1930],{"nctId":895,"briefTitle":896,"status":119,"phases":1917,"primaryCompletion":898,"completion":898,"start":899,"enrollment":707,"conditions":1918,"interventions":1919},[85],[901],[903,903,903,904],{"nctId":1921,"briefTitle":1922,"status":119,"phases":1923,"primaryCompletion":1924,"completion":1924,"start":1925,"enrollment":1926,"conditions":1927,"interventions":1929},"NCT01706835","Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors",[85],"2014-12","2012-10",18,[1928],"Advanced Solid Tumors",[903],{"nctId":1931,"briefTitle":1932,"status":119,"phases":1933,"primaryCompletion":1934,"completion":1934,"start":1935,"enrollment":1224,"conditions":1936,"interventions":1938},"NCT01673438","Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors",[85],"2014-04","2012-07",[1937],"Advanced Solid Tumor",[903],{"trials":1940,"activeCount":12},[1941,1945],{"nctId":366,"briefTitle":367,"status":201,"phases":1942,"primaryCompletion":344,"completion":369,"start":370,"enrollment":12,"conditions":1943,"interventions":1944},[86],[372],[217,152,374,153,140,142,143,144,146,375,148,317,336,294,376],{"nctId":1946,"briefTitle":1947,"status":119,"phases":1948,"primaryCompletion":1949,"completion":1949,"start":1950,"enrollment":1951,"conditions":1952,"interventions":1954},"NCT02200757","Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer",[86],"2017-05-15","2015-04-20",135,[1953],"Metastatic Small Cell Lung Cancer",[375,1955],"Topotecan",{"trials":1957,"activeCount":12},[1958],{"nctId":1959,"briefTitle":1960,"status":119,"phases":1961,"primaryCompletion":1962,"completion":1962,"start":1963,"enrollment":1964,"conditions":1965,"interventions":1967},"NCT02049905","Phase 3 Study to Treat Patients With Soft Tissue Sarcomas",[87],"2017-05","2014-01",433,[1966],"Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma",[375,1968],"Investigator's Choice Treatment",{"trials":1970,"activeCount":12},[],{"trials":1972,"activeCount":12},[],{"intervention":1974,"totalTrials":33,"cells":1975},"hAd5-S-Fusion+N-ETSD",{"EARLY_PHASE1":1976,"PHASE1":1978,"PHASE2":1991,"PHASE3":1993,"PHASE4":2005,"NA":2007},{"trials":1977,"activeCount":12},[],{"trials":1979,"activeCount":12},[1980],{"nctId":1981,"briefTitle":1982,"status":109,"phases":1983,"primaryCompletion":1984,"completion":1985,"start":1986,"enrollment":1987,"conditions":1988,"interventions":1989},"NCT04732468","COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1\u002FE2B\u002FE3-Deleted) Adenovirus Platform in Healthy Volunteers in USA",[85],"2022-07-11","2023-01-09","2021-02-24",28,[21],[1974,1990],"hAd5-SFusion+ N-ETSD",{"trials":1992,"activeCount":12},[],{"trials":1994,"activeCount":12},[1995],{"nctId":1996,"briefTitle":1997,"status":109,"phases":1998,"primaryCompletion":1999,"completion":2000,"start":2001,"enrollment":2002,"conditions":2003,"interventions":2004},"NCT06022224","A 2nd Generation E1\u002FE2B\u002FE3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL",[86,87],"2022-06-23","2023-07-19","2020-12-09",35,[18],[1974],{"trials":2006,"activeCount":12},[],{"trials":2008,"activeCount":12},[],{"intervention":564,"totalTrials":113,"cells":2010},{"EARLY_PHASE1":2011,"PHASE1":2013,"PHASE2":2015,"PHASE3":2017,"PHASE4":2023,"NA":2025},{"trials":2012,"activeCount":12},[],{"trials":2014,"activeCount":12},[],{"trials":2016,"activeCount":12},[],{"trials":2018,"activeCount":12},[2019],{"nctId":557,"briefTitle":558,"status":109,"phases":2020,"primaryCompletion":43,"completion":43,"start":560,"enrollment":561,"conditions":2021,"interventions":2022},[87],[372],[564,565,566,567,568,569,570,490,571,572,573,574,575,576],{"trials":2024,"activeCount":12},[],{"trials":2026,"activeCount":12},[],{"intervention":565,"totalTrials":113,"cells":2028},{"EARLY_PHASE1":2029,"PHASE1":2031,"PHASE2":2033,"PHASE3":2035,"PHASE4":2041,"NA":2043},{"trials":2030,"activeCount":12},[],{"trials":2032,"activeCount":12},[],{"trials":2034,"activeCount":12},[],{"trials":2036,"activeCount":12},[2037],{"nctId":557,"briefTitle":558,"status":109,"phases":2038,"primaryCompletion":43,"completion":43,"start":560,"enrollment":561,"conditions":2039,"interventions":2040},[87],[372],[564,565,566,567,568,569,570,490,571,572,573,574,575,576],{"trials":2042,"activeCount":12},[],{"trials":2044,"activeCount":12},[],{"intervention":566,"totalTrials":113,"cells":2046},{"EARLY_PHASE1":2047,"PHASE1":2049,"PHASE2":2051,"PHASE3":2053,"PHASE4":2059,"NA":2061},{"trials":2048,"activeCount":12},[],{"trials":2050,"activeCount":12},[],{"trials":2052,"activeCount":12},[],{"trials":2054,"activeCount":12},[2055],{"nctId":557,"briefTitle":558,"status":109,"phases":2056,"primaryCompletion":43,"completion":43,"start":560,"enrollment":561,"conditions":2057,"interventions":2058},[87],[372],[564,565,566,567,568,569,570,490,571,572,573,574,575,576],{"trials":2060,"activeCount":12},[],{"trials":2062,"activeCount":12},[],{"intervention":567,"totalTrials":113,"cells":2064},{"EARLY_PHASE1":2065,"PHASE1":2067,"PHASE2":2069,"PHASE3":2071,"PHASE4":2077,"NA":2079},{"trials":2066,"activeCount":12},[],{"trials":2068,"activeCount":12},[],{"trials":2070,"activeCount":12},[],{"trials":2072,"activeCount":12},[2073],{"nctId":557,"briefTitle":558,"status":109,"phases":2074,"primaryCompletion":43,"completion":43,"start":560,"enrollment":561,"conditions":2075,"interventions":2076},[87],[372],[564,565,566,567,568,569,570,490,571,572,573,574,575,576],{"trials":2078,"activeCount":12},[],{"trials":2080,"activeCount":12},[],{"intervention":568,"totalTrials":113,"cells":2082},{"EARLY_PHASE1":2083,"PHASE1":2085,"PHASE2":2087,"PHASE3":2089,"PHASE4":2095,"NA":2097},{"trials":2084,"activeCount":12},[],{"trials":2086,"activeCount":12},[],{"trials":2088,"activeCount":12},[],{"trials":2090,"activeCount":12},[2091],{"nctId":557,"briefTitle":558,"status":109,"phases":2092,"primaryCompletion":43,"completion":43,"start":560,"enrollment":561,"conditions":2093,"interventions":2094},[87],[372],[564,565,566,567,568,569,570,490,571,572,573,574,575,576],{"trials":2096,"activeCount":12},[],{"trials":2098,"activeCount":12},[],{"intervention":569,"totalTrials":113,"cells":2100},{"EARLY_PHASE1":2101,"PHASE1":2103,"PHASE2":2105,"PHASE3":2107,"PHASE4":2113,"NA":2115},{"trials":2102,"activeCount":12},[],{"trials":2104,"activeCount":12},[],{"trials":2106,"activeCount":12},[],{"trials":2108,"activeCount":12},[2109],{"nctId":557,"briefTitle":558,"status":109,"phases":2110,"primaryCompletion":43,"completion":43,"start":560,"enrollment":561,"conditions":2111,"interventions":2112},[87],[372],[564,565,566,567,568,569,570,490,571,572,573,574,575,576],{"trials":2114,"activeCount":12},[],{"trials":2116,"activeCount":12},[],{"intervention":570,"totalTrials":113,"cells":2118},{"EARLY_PHASE1":2119,"PHASE1":2121,"PHASE2":2123,"PHASE3":2125,"PHASE4":2131,"NA":2133},{"trials":2120,"activeCount":12},[],{"trials":2122,"activeCount":12},[],{"trials":2124,"activeCount":12},[],{"trials":2126,"activeCount":12},[2127],{"nctId":557,"briefTitle":558,"status":109,"phases":2128,"primaryCompletion":43,"completion":43,"start":560,"enrollment":561,"conditions":2129,"interventions":2130},[87],[372],[564,565,566,567,568,569,570,490,571,572,573,574,575,576],{"trials":2132,"activeCount":12},[],{"trials":2134,"activeCount":12},[],{"intervention":571,"totalTrials":113,"cells":2136},{"EARLY_PHASE1":2137,"PHASE1":2139,"PHASE2":2141,"PHASE3":2143,"PHASE4":2149,"NA":2151},{"trials":2138,"activeCount":12},[],{"trials":2140,"activeCount":12},[],{"trials":2142,"activeCount":12},[],{"trials":2144,"activeCount":12},[2145],{"nctId":557,"briefTitle":558,"status":109,"phases":2146,"primaryCompletion":43,"completion":43,"start":560,"enrollment":561,"conditions":2147,"interventions":2148},[87],[372],[564,565,566,567,568,569,570,490,571,572,573,574,575,576],{"trials":2150,"activeCount":12},[],{"trials":2152,"activeCount":12},[],{"intervention":572,"totalTrials":113,"cells":2154},{"EARLY_PHASE1":2155,"PHASE1":2157,"PHASE2":2159,"PHASE3":2161,"PHASE4":2167,"NA":2169},{"trials":2156,"activeCount":12},[],{"trials":2158,"activeCount":12},[],{"trials":2160,"activeCount":12},[],{"trials":2162,"activeCount":12},[2163],{"nctId":557,"briefTitle":558,"status":109,"phases":2164,"primaryCompletion":43,"completion":43,"start":560,"enrollment":561,"conditions":2165,"interventions":2166},[87],[372],[564,565,566,567,568,569,570,490,571,572,573,574,575,576],{"trials":2168,"activeCount":12},[],{"trials":2170,"activeCount":12},[],{"intervention":573,"totalTrials":113,"cells":2172},{"EARLY_PHASE1":2173,"PHASE1":2175,"PHASE2":2177,"PHASE3":2179,"PHASE4":2185,"NA":2187},{"trials":2174,"activeCount":12},[],{"trials":2176,"activeCount":12},[],{"trials":2178,"activeCount":12},[],{"trials":2180,"activeCount":12},[2181],{"nctId":557,"briefTitle":558,"status":109,"phases":2182,"primaryCompletion":43,"completion":43,"start":560,"enrollment":561,"conditions":2183,"interventions":2184},[87],[372],[564,565,566,567,568,569,570,490,571,572,573,574,575,576],{"trials":2186,"activeCount":12},[],{"trials":2188,"activeCount":12},[],{"intervention":574,"totalTrials":113,"cells":2190},{"EARLY_PHASE1":2191,"PHASE1":2193,"PHASE2":2195,"PHASE3":2197,"PHASE4":2203,"NA":2205},{"trials":2192,"activeCount":12},[],{"trials":2194,"activeCount":12},[],{"trials":2196,"activeCount":12},[],{"trials":2198,"activeCount":12},[2199],{"nctId":557,"briefTitle":558,"status":109,"phases":2200,"primaryCompletion":43,"completion":43,"start":560,"enrollment":561,"conditions":2201,"interventions":2202},[87],[372],[564,565,566,567,568,569,570,490,571,572,573,574,575,576],{"trials":2204,"activeCount":12},[],{"trials":2206,"activeCount":12},[],{"intervention":575,"totalTrials":113,"cells":2208},{"EARLY_PHASE1":2209,"PHASE1":2211,"PHASE2":2213,"PHASE3":2215,"PHASE4":2221,"NA":2223},{"trials":2210,"activeCount":12},[],{"trials":2212,"activeCount":12},[],{"trials":2214,"activeCount":12},[],{"trials":2216,"activeCount":12},[2217],{"nctId":557,"briefTitle":558,"status":109,"phases":2218,"primaryCompletion":43,"completion":43,"start":560,"enrollment":561,"conditions":2219,"interventions":2220},[87],[372],[564,565,566,567,568,569,570,490,571,572,573,574,575,576],{"trials":2222,"activeCount":12},[],{"trials":2224,"activeCount":12},[],{"intervention":576,"totalTrials":113,"cells":2226},{"EARLY_PHASE1":2227,"PHASE1":2229,"PHASE2":2231,"PHASE3":2233,"PHASE4":2239,"NA":2241},{"trials":2228,"activeCount":12},[],{"trials":2230,"activeCount":12},[],{"trials":2232,"activeCount":12},[],{"trials":2234,"activeCount":12},[2235],{"nctId":557,"briefTitle":558,"status":109,"phases":2236,"primaryCompletion":43,"completion":43,"start":560,"enrollment":561,"conditions":2237,"interventions":2238},[87],[372],[564,565,566,567,568,569,570,490,571,572,573,574,575,576],{"trials":2240,"activeCount":12},[],{"trials":2242,"activeCount":12},[],{"intervention":1968,"totalTrials":113,"cells":2244},{"EARLY_PHASE1":2245,"PHASE1":2247,"PHASE2":2249,"PHASE3":2251,"PHASE4":2257,"NA":2259},{"trials":2246,"activeCount":12},[],{"trials":2248,"activeCount":12},[],{"trials":2250,"activeCount":12},[],{"trials":2252,"activeCount":12},[2253],{"nctId":1959,"briefTitle":1960,"status":119,"phases":2254,"primaryCompletion":1962,"completion":1962,"start":1963,"enrollment":1964,"conditions":2255,"interventions":2256},[87],[1966],[375,1968],{"trials":2258,"activeCount":12},[],{"trials":2260,"activeCount":12},[],{"intervention":742,"totalTrials":113,"cells":2262},{"EARLY_PHASE1":2263,"PHASE1":2265,"PHASE2":2267,"PHASE3":2269,"PHASE4":2275,"NA":2277},{"trials":2264,"activeCount":12},[],{"trials":2266,"activeCount":12},[],{"trials":2268,"activeCount":12},[],{"trials":2270,"activeCount":12},[2271],{"nctId":732,"briefTitle":733,"status":201,"phases":2272,"primaryCompletion":735,"completion":163,"start":736,"enrollment":12,"conditions":2273,"interventions":2274},[87],[738,739,28,30,740],[694,742],{"trials":2276,"activeCount":12},[],{"trials":2278,"activeCount":12},[],{"intervention":148,"totalTrials":8,"cells":2280},{"EARLY_PHASE1":2281,"PHASE1":2283,"PHASE2":2285,"PHASE3":2375,"PHASE4":2377,"NA":2379},{"trials":2282,"activeCount":12},[],{"trials":2284,"activeCount":12},[],{"trials":2286,"activeCount":12},[2287,2291,2295,2299,2303,2307,2311,2315,2319,2323,2327,2331,2335,2339,2343,2347,2351,2355,2359,2363,2367,2371],{"nctId":767,"briefTitle":768,"status":201,"phases":2288,"primaryCompletion":770,"completion":382,"start":771,"enrollment":12,"conditions":2289,"interventions":2290},[85,86],[773,774],[335,317,142,143,146,336,148,151,153],{"nctId":309,"briefTitle":310,"status":109,"phases":2292,"primaryCompletion":312,"completion":313,"start":314,"enrollment":19,"conditions":2293,"interventions":2294},[85,86],[15],[139,317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":130,"briefTitle":131,"status":109,"phases":2296,"primaryCompletion":133,"completion":134,"start":135,"enrollment":19,"conditions":2297,"interventions":2298},[85,86],[137],[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,44],{"nctId":325,"briefTitle":326,"status":109,"phases":2300,"primaryCompletion":328,"completion":329,"start":330,"enrollment":33,"conditions":2301,"interventions":2302},[85,86],[332,333],[335,317,140,141,142,143,144,145,146,336,148,150,151,153,184,155,217,319,337],{"nctId":339,"briefTitle":340,"status":201,"phases":2304,"primaryCompletion":342,"completion":343,"start":344,"enrollment":12,"conditions":2305,"interventions":2306},[86],[346],[77,217,139,317,140,141,142,143,144,145,146,336,148,170,150,153,184,155,319],{"nctId":173,"briefTitle":174,"status":109,"phases":2308,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":2309,"interventions":2310},[85,86],[181],[139,44,140,142,143,144,145,146,147,183,149,150,152,153,184,155,156],{"nctId":797,"briefTitle":798,"status":201,"phases":2312,"primaryCompletion":800,"completion":382,"start":383,"enrollment":12,"conditions":2313,"interventions":2314},[85,86],[802],[148,170,150,153,423,804,155,805,806,319,317,141,142,143,144,146,807],{"nctId":353,"briefTitle":354,"status":109,"phases":2316,"primaryCompletion":356,"completion":357,"start":358,"enrollment":16,"conditions":2317,"interventions":2318},[85,86],[15],[317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":366,"briefTitle":367,"status":201,"phases":2320,"primaryCompletion":344,"completion":369,"start":370,"enrollment":12,"conditions":2321,"interventions":2322},[86],[372],[217,152,374,153,140,142,143,144,146,375,148,317,336,294,376],{"nctId":378,"briefTitle":379,"status":201,"phases":2324,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2325,"interventions":2326},[85,86],[385],[183,149,387,388,389,374,390,391,392,393,317,140,141,142,143,144,145,146,336],{"nctId":220,"briefTitle":221,"status":201,"phases":2328,"primaryCompletion":223,"completion":223,"start":224,"enrollment":12,"conditions":2329,"interventions":2330},[85,86],[226,227],[140,144,147,183,150,153,184,155,156,229,230,142,143,145,146,151,44],{"nctId":410,"briefTitle":411,"status":109,"phases":2332,"primaryCompletion":133,"completion":413,"start":414,"enrollment":24,"conditions":2333,"interventions":2334},[85,86],[15],[139,317,140,141,142,143,144,145,146,147,149,150,153,154,155,156,319,148],{"nctId":418,"briefTitle":419,"status":201,"phases":2336,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2337,"interventions":2338},[85,86],[26],[148,170,150,152,153,423,155,156,424,317,142,143,146,336],{"nctId":426,"briefTitle":427,"status":201,"phases":2340,"primaryCompletion":429,"completion":343,"start":430,"enrollment":12,"conditions":2341,"interventions":2342},[86],[432],[155,184,139,156,140,142,143,144,145,146,148,317,336,153,434,435],{"nctId":841,"briefTitle":842,"status":201,"phases":2344,"primaryCompletion":381,"completion":382,"start":844,"enrollment":12,"conditions":2345,"interventions":2346},[85,86],[846],[183,170,150,152,389,184,390,391,848,443,393,319,317,140,141,142,143,144,145,146,336],{"nctId":850,"briefTitle":851,"status":201,"phases":2348,"primaryCompletion":381,"completion":382,"start":344,"enrollment":12,"conditions":2349,"interventions":2350},[85,86],[854],[183,149,387,856,153,184,390,391,848,443,393,857,317,140,141,142,143,144,145,146,336],{"nctId":437,"briefTitle":438,"status":201,"phases":2352,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2353,"interventions":2354},[85,86],[441],[148,170,150,151,152,389,184,390,391,392,443,393,317,140,141,142,143,144,145,146,336],{"nctId":445,"briefTitle":446,"status":201,"phases":2356,"primaryCompletion":381,"completion":448,"start":383,"enrollment":12,"conditions":2357,"interventions":2358},[85,86],[450],[183,149,387,389,184,391,392,393,319,197,317,143,336],{"nctId":262,"briefTitle":263,"status":109,"phases":2360,"primaryCompletion":265,"completion":266,"start":267,"enrollment":179,"conditions":2361,"interventions":2362},[86],[26],[148,44,270],{"nctId":453,"briefTitle":454,"status":201,"phases":2364,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2365,"interventions":2366},[85,86],[181],[183,149,387,388,389,184,155,392,393,317,140,142,143,144,145,146,336],{"nctId":459,"briefTitle":460,"status":201,"phases":2368,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2369,"interventions":2370},[85,86],[463],[148,170,150,152,153,423,155,392,465,424,317,140,142,143,145,146,336],{"nctId":467,"briefTitle":468,"status":109,"phases":2372,"primaryCompletion":470,"completion":357,"start":471,"enrollment":24,"conditions":2373,"interventions":2374},[85,86],[15],[153,319,150,184,155,392,149,183,317,474,140,144],{"trials":2376,"activeCount":12},[],{"trials":2378,"activeCount":12},[],{"trials":2380,"activeCount":12},[],{"intervention":317,"totalTrials":1926,"cells":2382},{"EARLY_PHASE1":2383,"PHASE1":2385,"PHASE2":2387,"PHASE3":2461,"PHASE4":2463,"NA":2465},{"trials":2384,"activeCount":12},[],{"trials":2386,"activeCount":12},[],{"trials":2388,"activeCount":12},[2389,2393,2397,2401,2405,2409,2413,2417,2421,2425,2429,2433,2437,2441,2445,2449,2453,2457],{"nctId":767,"briefTitle":768,"status":201,"phases":2390,"primaryCompletion":770,"completion":382,"start":771,"enrollment":12,"conditions":2391,"interventions":2392},[85,86],[773,774],[335,317,142,143,146,336,148,151,153],{"nctId":309,"briefTitle":310,"status":109,"phases":2394,"primaryCompletion":312,"completion":313,"start":314,"enrollment":19,"conditions":2395,"interventions":2396},[85,86],[15],[139,317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":325,"briefTitle":326,"status":109,"phases":2398,"primaryCompletion":328,"completion":329,"start":330,"enrollment":33,"conditions":2399,"interventions":2400},[85,86],[332,333],[335,317,140,141,142,143,144,145,146,336,148,150,151,153,184,155,217,319,337],{"nctId":339,"briefTitle":340,"status":201,"phases":2402,"primaryCompletion":342,"completion":343,"start":344,"enrollment":12,"conditions":2403,"interventions":2404},[86],[346],[77,217,139,317,140,141,142,143,144,145,146,336,148,170,150,153,184,155,319],{"nctId":797,"briefTitle":798,"status":201,"phases":2406,"primaryCompletion":800,"completion":382,"start":383,"enrollment":12,"conditions":2407,"interventions":2408},[85,86],[802],[148,170,150,153,423,804,155,805,806,319,317,141,142,143,144,146,807],{"nctId":353,"briefTitle":354,"status":109,"phases":2410,"primaryCompletion":356,"completion":357,"start":358,"enrollment":16,"conditions":2411,"interventions":2412},[85,86],[15],[317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":366,"briefTitle":367,"status":201,"phases":2414,"primaryCompletion":344,"completion":369,"start":370,"enrollment":12,"conditions":2415,"interventions":2416},[86],[372],[217,152,374,153,140,142,143,144,146,375,148,317,336,294,376],{"nctId":378,"briefTitle":379,"status":201,"phases":2418,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2419,"interventions":2420},[85,86],[385],[183,149,387,388,389,374,390,391,392,393,317,140,141,142,143,144,145,146,336],{"nctId":410,"briefTitle":411,"status":109,"phases":2422,"primaryCompletion":133,"completion":413,"start":414,"enrollment":24,"conditions":2423,"interventions":2424},[85,86],[15],[139,317,140,141,142,143,144,145,146,147,149,150,153,154,155,156,319,148],{"nctId":418,"briefTitle":419,"status":201,"phases":2426,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2427,"interventions":2428},[85,86],[26],[148,170,150,152,153,423,155,156,424,317,142,143,146,336],{"nctId":426,"briefTitle":427,"status":201,"phases":2430,"primaryCompletion":429,"completion":343,"start":430,"enrollment":12,"conditions":2431,"interventions":2432},[86],[432],[155,184,139,156,140,142,143,144,145,146,148,317,336,153,434,435],{"nctId":841,"briefTitle":842,"status":201,"phases":2434,"primaryCompletion":381,"completion":382,"start":844,"enrollment":12,"conditions":2435,"interventions":2436},[85,86],[846],[183,170,150,152,389,184,390,391,848,443,393,319,317,140,141,142,143,144,145,146,336],{"nctId":850,"briefTitle":851,"status":201,"phases":2438,"primaryCompletion":381,"completion":382,"start":344,"enrollment":12,"conditions":2439,"interventions":2440},[85,86],[854],[183,149,387,856,153,184,390,391,848,443,393,857,317,140,141,142,143,144,145,146,336],{"nctId":437,"briefTitle":438,"status":201,"phases":2442,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2443,"interventions":2444},[85,86],[441],[148,170,150,151,152,389,184,390,391,392,443,393,317,140,141,142,143,144,145,146,336],{"nctId":445,"briefTitle":446,"status":201,"phases":2446,"primaryCompletion":381,"completion":448,"start":383,"enrollment":12,"conditions":2447,"interventions":2448},[85,86],[450],[183,149,387,389,184,391,392,393,319,197,317,143,336],{"nctId":453,"briefTitle":454,"status":201,"phases":2450,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2451,"interventions":2452},[85,86],[181],[183,149,387,388,389,184,155,392,393,317,140,142,143,144,145,146,336],{"nctId":459,"briefTitle":460,"status":201,"phases":2454,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2455,"interventions":2456},[85,86],[463],[148,170,150,152,153,423,155,392,465,424,317,140,142,143,145,146,336],{"nctId":467,"briefTitle":468,"status":109,"phases":2458,"primaryCompletion":470,"completion":357,"start":471,"enrollment":24,"conditions":2459,"interventions":2460},[85,86],[15],[153,319,150,184,155,392,149,183,317,474,140,144],{"trials":2462,"activeCount":12},[],{"trials":2464,"activeCount":12},[],{"trials":2466,"activeCount":12},[],{"intervention":143,"totalTrials":1926,"cells":2468},{"EARLY_PHASE1":2469,"PHASE1":2471,"PHASE2":2473,"PHASE3":2547,"PHASE4":2549,"NA":2551},{"trials":2470,"activeCount":12},[],{"trials":2472,"activeCount":12},[],{"trials":2474,"activeCount":12},[2475,2479,2483,2487,2491,2495,2499,2503,2507,2511,2515,2519,2523,2527,2531,2535,2539,2543],{"nctId":767,"briefTitle":768,"status":201,"phases":2476,"primaryCompletion":770,"completion":382,"start":771,"enrollment":12,"conditions":2477,"interventions":2478},[85,86],[773,774],[335,317,142,143,146,336,148,151,153],{"nctId":130,"briefTitle":131,"status":109,"phases":2480,"primaryCompletion":133,"completion":134,"start":135,"enrollment":19,"conditions":2481,"interventions":2482},[85,86],[137],[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,44],{"nctId":325,"briefTitle":326,"status":109,"phases":2484,"primaryCompletion":328,"completion":329,"start":330,"enrollment":33,"conditions":2485,"interventions":2486},[85,86],[332,333],[335,317,140,141,142,143,144,145,146,336,148,150,151,153,184,155,217,319,337],{"nctId":339,"briefTitle":340,"status":201,"phases":2488,"primaryCompletion":342,"completion":343,"start":344,"enrollment":12,"conditions":2489,"interventions":2490},[86],[346],[77,217,139,317,140,141,142,143,144,145,146,336,148,170,150,153,184,155,319],{"nctId":173,"briefTitle":174,"status":109,"phases":2492,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":2493,"interventions":2494},[85,86],[181],[139,44,140,142,143,144,145,146,147,183,149,150,152,153,184,155,156],{"nctId":797,"briefTitle":798,"status":201,"phases":2496,"primaryCompletion":800,"completion":382,"start":383,"enrollment":12,"conditions":2497,"interventions":2498},[85,86],[802],[148,170,150,153,423,804,155,805,806,319,317,141,142,143,144,146,807],{"nctId":366,"briefTitle":367,"status":201,"phases":2500,"primaryCompletion":344,"completion":369,"start":370,"enrollment":12,"conditions":2501,"interventions":2502},[86],[372],[217,152,374,153,140,142,143,144,146,375,148,317,336,294,376],{"nctId":378,"briefTitle":379,"status":201,"phases":2504,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2505,"interventions":2506},[85,86],[385],[183,149,387,388,389,374,390,391,392,393,317,140,141,142,143,144,145,146,336],{"nctId":220,"briefTitle":221,"status":201,"phases":2508,"primaryCompletion":223,"completion":223,"start":224,"enrollment":12,"conditions":2509,"interventions":2510},[85,86],[226,227],[140,144,147,183,150,153,184,155,156,229,230,142,143,145,146,151,44],{"nctId":410,"briefTitle":411,"status":109,"phases":2512,"primaryCompletion":133,"completion":413,"start":414,"enrollment":24,"conditions":2513,"interventions":2514},[85,86],[15],[139,317,140,141,142,143,144,145,146,147,149,150,153,154,155,156,319,148],{"nctId":418,"briefTitle":419,"status":201,"phases":2516,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2517,"interventions":2518},[85,86],[26],[148,170,150,152,153,423,155,156,424,317,142,143,146,336],{"nctId":426,"briefTitle":427,"status":201,"phases":2520,"primaryCompletion":429,"completion":343,"start":430,"enrollment":12,"conditions":2521,"interventions":2522},[86],[432],[155,184,139,156,140,142,143,144,145,146,148,317,336,153,434,435],{"nctId":841,"briefTitle":842,"status":201,"phases":2524,"primaryCompletion":381,"completion":382,"start":844,"enrollment":12,"conditions":2525,"interventions":2526},[85,86],[846],[183,170,150,152,389,184,390,391,848,443,393,319,317,140,141,142,143,144,145,146,336],{"nctId":850,"briefTitle":851,"status":201,"phases":2528,"primaryCompletion":381,"completion":382,"start":344,"enrollment":12,"conditions":2529,"interventions":2530},[85,86],[854],[183,149,387,856,153,184,390,391,848,443,393,857,317,140,141,142,143,144,145,146,336],{"nctId":437,"briefTitle":438,"status":201,"phases":2532,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2533,"interventions":2534},[85,86],[441],[148,170,150,151,152,389,184,390,391,392,443,393,317,140,141,142,143,144,145,146,336],{"nctId":445,"briefTitle":446,"status":201,"phases":2536,"primaryCompletion":381,"completion":448,"start":383,"enrollment":12,"conditions":2537,"interventions":2538},[85,86],[450],[183,149,387,389,184,391,392,393,319,197,317,143,336],{"nctId":453,"briefTitle":454,"status":201,"phases":2540,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2541,"interventions":2542},[85,86],[181],[183,149,387,388,389,184,155,392,393,317,140,142,143,144,145,146,336],{"nctId":459,"briefTitle":460,"status":201,"phases":2544,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2545,"interventions":2546},[85,86],[463],[148,170,150,152,153,423,155,392,465,424,317,140,142,143,145,146,336],{"trials":2548,"activeCount":12},[],{"trials":2550,"activeCount":12},[],{"trials":2552,"activeCount":12},[],{"intervention":150,"totalTrials":1926,"cells":2554},{"EARLY_PHASE1":2555,"PHASE1":2557,"PHASE2":2559,"PHASE3":2633,"PHASE4":2635,"NA":2637},{"trials":2556,"activeCount":12},[],{"trials":2558,"activeCount":12},[],{"trials":2560,"activeCount":12},[2561,2565,2569,2573,2577,2581,2585,2589,2593,2597,2601,2605,2609,2613,2617,2621,2625,2629],{"nctId":309,"briefTitle":310,"status":109,"phases":2562,"primaryCompletion":312,"completion":313,"start":314,"enrollment":19,"conditions":2563,"interventions":2564},[85,86],[15],[139,317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":130,"briefTitle":131,"status":109,"phases":2566,"primaryCompletion":133,"completion":134,"start":135,"enrollment":19,"conditions":2567,"interventions":2568},[85,86],[137],[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,44],{"nctId":325,"briefTitle":326,"status":109,"phases":2570,"primaryCompletion":328,"completion":329,"start":330,"enrollment":33,"conditions":2571,"interventions":2572},[85,86],[332,333],[335,317,140,141,142,143,144,145,146,336,148,150,151,153,184,155,217,319,337],{"nctId":339,"briefTitle":340,"status":201,"phases":2574,"primaryCompletion":342,"completion":343,"start":344,"enrollment":12,"conditions":2575,"interventions":2576},[86],[346],[77,217,139,317,140,141,142,143,144,145,146,336,148,170,150,153,184,155,319],{"nctId":173,"briefTitle":174,"status":109,"phases":2578,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":2579,"interventions":2580},[85,86],[181],[139,44,140,142,143,144,145,146,147,183,149,150,152,153,184,155,156],{"nctId":797,"briefTitle":798,"status":201,"phases":2582,"primaryCompletion":800,"completion":382,"start":383,"enrollment":12,"conditions":2583,"interventions":2584},[85,86],[802],[148,170,150,153,423,804,155,805,806,319,317,141,142,143,144,146,807],{"nctId":353,"briefTitle":354,"status":109,"phases":2586,"primaryCompletion":356,"completion":357,"start":358,"enrollment":16,"conditions":2587,"interventions":2588},[85,86],[15],[317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":378,"briefTitle":379,"status":201,"phases":2590,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2591,"interventions":2592},[85,86],[385],[183,149,387,388,389,374,390,391,392,393,317,140,141,142,143,144,145,146,336],{"nctId":220,"briefTitle":221,"status":201,"phases":2594,"primaryCompletion":223,"completion":223,"start":224,"enrollment":12,"conditions":2595,"interventions":2596},[85,86],[226,227],[140,144,147,183,150,153,184,155,156,229,230,142,143,145,146,151,44],{"nctId":410,"briefTitle":411,"status":109,"phases":2598,"primaryCompletion":133,"completion":413,"start":414,"enrollment":24,"conditions":2599,"interventions":2600},[85,86],[15],[139,317,140,141,142,143,144,145,146,147,149,150,153,154,155,156,319,148],{"nctId":418,"briefTitle":419,"status":201,"phases":2602,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2603,"interventions":2604},[85,86],[26],[148,170,150,152,153,423,155,156,424,317,142,143,146,336],{"nctId":841,"briefTitle":842,"status":201,"phases":2606,"primaryCompletion":381,"completion":382,"start":844,"enrollment":12,"conditions":2607,"interventions":2608},[85,86],[846],[183,170,150,152,389,184,390,391,848,443,393,319,317,140,141,142,143,144,145,146,336],{"nctId":850,"briefTitle":851,"status":201,"phases":2610,"primaryCompletion":381,"completion":382,"start":344,"enrollment":12,"conditions":2611,"interventions":2612},[85,86],[854],[183,149,387,856,153,184,390,391,848,443,393,857,317,140,141,142,143,144,145,146,336],{"nctId":437,"briefTitle":438,"status":201,"phases":2614,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2615,"interventions":2616},[85,86],[441],[148,170,150,151,152,389,184,390,391,392,443,393,317,140,141,142,143,144,145,146,336],{"nctId":445,"briefTitle":446,"status":201,"phases":2618,"primaryCompletion":381,"completion":448,"start":383,"enrollment":12,"conditions":2619,"interventions":2620},[85,86],[450],[183,149,387,389,184,391,392,393,319,197,317,143,336],{"nctId":453,"briefTitle":454,"status":201,"phases":2622,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2623,"interventions":2624},[85,86],[181],[183,149,387,388,389,184,155,392,393,317,140,142,143,144,145,146,336],{"nctId":459,"briefTitle":460,"status":201,"phases":2626,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2627,"interventions":2628},[85,86],[463],[148,170,150,152,153,423,155,392,465,424,317,140,142,143,145,146,336],{"nctId":467,"briefTitle":468,"status":109,"phases":2630,"primaryCompletion":470,"completion":357,"start":471,"enrollment":24,"conditions":2631,"interventions":2632},[85,86],[15],[153,319,150,184,155,392,149,183,317,474,140,144],{"trials":2634,"activeCount":12},[],{"trials":2636,"activeCount":12},[],{"trials":2638,"activeCount":12},[],{"intervention":142,"totalTrials":92,"cells":2640},{"EARLY_PHASE1":2641,"PHASE1":2643,"PHASE2":2645,"PHASE3":2715,"PHASE4":2717,"NA":2719},{"trials":2642,"activeCount":12},[],{"trials":2644,"activeCount":12},[],{"trials":2646,"activeCount":12},[2647,2651,2655,2659,2663,2667,2671,2675,2679,2683,2687,2691,2695,2699,2703,2707,2711],{"nctId":767,"briefTitle":768,"status":201,"phases":2648,"primaryCompletion":770,"completion":382,"start":771,"enrollment":12,"conditions":2649,"interventions":2650},[85,86],[773,774],[335,317,142,143,146,336,148,151,153],{"nctId":130,"briefTitle":131,"status":109,"phases":2652,"primaryCompletion":133,"completion":134,"start":135,"enrollment":19,"conditions":2653,"interventions":2654},[85,86],[137],[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,44],{"nctId":325,"briefTitle":326,"status":109,"phases":2656,"primaryCompletion":328,"completion":329,"start":330,"enrollment":33,"conditions":2657,"interventions":2658},[85,86],[332,333],[335,317,140,141,142,143,144,145,146,336,148,150,151,153,184,155,217,319,337],{"nctId":339,"briefTitle":340,"status":201,"phases":2660,"primaryCompletion":342,"completion":343,"start":344,"enrollment":12,"conditions":2661,"interventions":2662},[86],[346],[77,217,139,317,140,141,142,143,144,145,146,336,148,170,150,153,184,155,319],{"nctId":173,"briefTitle":174,"status":109,"phases":2664,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":2665,"interventions":2666},[85,86],[181],[139,44,140,142,143,144,145,146,147,183,149,150,152,153,184,155,156],{"nctId":797,"briefTitle":798,"status":201,"phases":2668,"primaryCompletion":800,"completion":382,"start":383,"enrollment":12,"conditions":2669,"interventions":2670},[85,86],[802],[148,170,150,153,423,804,155,805,806,319,317,141,142,143,144,146,807],{"nctId":366,"briefTitle":367,"status":201,"phases":2672,"primaryCompletion":344,"completion":369,"start":370,"enrollment":12,"conditions":2673,"interventions":2674},[86],[372],[217,152,374,153,140,142,143,144,146,375,148,317,336,294,376],{"nctId":378,"briefTitle":379,"status":201,"phases":2676,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2677,"interventions":2678},[85,86],[385],[183,149,387,388,389,374,390,391,392,393,317,140,141,142,143,144,145,146,336],{"nctId":220,"briefTitle":221,"status":201,"phases":2680,"primaryCompletion":223,"completion":223,"start":224,"enrollment":12,"conditions":2681,"interventions":2682},[85,86],[226,227],[140,144,147,183,150,153,184,155,156,229,230,142,143,145,146,151,44],{"nctId":410,"briefTitle":411,"status":109,"phases":2684,"primaryCompletion":133,"completion":413,"start":414,"enrollment":24,"conditions":2685,"interventions":2686},[85,86],[15],[139,317,140,141,142,143,144,145,146,147,149,150,153,154,155,156,319,148],{"nctId":418,"briefTitle":419,"status":201,"phases":2688,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2689,"interventions":2690},[85,86],[26],[148,170,150,152,153,423,155,156,424,317,142,143,146,336],{"nctId":426,"briefTitle":427,"status":201,"phases":2692,"primaryCompletion":429,"completion":343,"start":430,"enrollment":12,"conditions":2693,"interventions":2694},[86],[432],[155,184,139,156,140,142,143,144,145,146,148,317,336,153,434,435],{"nctId":841,"briefTitle":842,"status":201,"phases":2696,"primaryCompletion":381,"completion":382,"start":844,"enrollment":12,"conditions":2697,"interventions":2698},[85,86],[846],[183,170,150,152,389,184,390,391,848,443,393,319,317,140,141,142,143,144,145,146,336],{"nctId":850,"briefTitle":851,"status":201,"phases":2700,"primaryCompletion":381,"completion":382,"start":344,"enrollment":12,"conditions":2701,"interventions":2702},[85,86],[854],[183,149,387,856,153,184,390,391,848,443,393,857,317,140,141,142,143,144,145,146,336],{"nctId":437,"briefTitle":438,"status":201,"phases":2704,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2705,"interventions":2706},[85,86],[441],[148,170,150,151,152,389,184,390,391,392,443,393,317,140,141,142,143,144,145,146,336],{"nctId":453,"briefTitle":454,"status":201,"phases":2708,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2709,"interventions":2710},[85,86],[181],[183,149,387,388,389,184,155,392,393,317,140,142,143,144,145,146,336],{"nctId":459,"briefTitle":460,"status":201,"phases":2712,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2713,"interventions":2714},[85,86],[463],[148,170,150,152,153,423,155,392,465,424,317,140,142,143,145,146,336],{"trials":2716,"activeCount":12},[],{"trials":2718,"activeCount":12},[],{"trials":2720,"activeCount":12},[],{"intervention":146,"totalTrials":92,"cells":2722},{"EARLY_PHASE1":2723,"PHASE1":2725,"PHASE2":2727,"PHASE3":2797,"PHASE4":2799,"NA":2801},{"trials":2724,"activeCount":12},[],{"trials":2726,"activeCount":12},[],{"trials":2728,"activeCount":12},[2729,2733,2737,2741,2745,2749,2753,2757,2761,2765,2769,2773,2777,2781,2785,2789,2793],{"nctId":767,"briefTitle":768,"status":201,"phases":2730,"primaryCompletion":770,"completion":382,"start":771,"enrollment":12,"conditions":2731,"interventions":2732},[85,86],[773,774],[335,317,142,143,146,336,148,151,153],{"nctId":130,"briefTitle":131,"status":109,"phases":2734,"primaryCompletion":133,"completion":134,"start":135,"enrollment":19,"conditions":2735,"interventions":2736},[85,86],[137],[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,44],{"nctId":325,"briefTitle":326,"status":109,"phases":2738,"primaryCompletion":328,"completion":329,"start":330,"enrollment":33,"conditions":2739,"interventions":2740},[85,86],[332,333],[335,317,140,141,142,143,144,145,146,336,148,150,151,153,184,155,217,319,337],{"nctId":339,"briefTitle":340,"status":201,"phases":2742,"primaryCompletion":342,"completion":343,"start":344,"enrollment":12,"conditions":2743,"interventions":2744},[86],[346],[77,217,139,317,140,141,142,143,144,145,146,336,148,170,150,153,184,155,319],{"nctId":173,"briefTitle":174,"status":109,"phases":2746,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":2747,"interventions":2748},[85,86],[181],[139,44,140,142,143,144,145,146,147,183,149,150,152,153,184,155,156],{"nctId":797,"briefTitle":798,"status":201,"phases":2750,"primaryCompletion":800,"completion":382,"start":383,"enrollment":12,"conditions":2751,"interventions":2752},[85,86],[802],[148,170,150,153,423,804,155,805,806,319,317,141,142,143,144,146,807],{"nctId":366,"briefTitle":367,"status":201,"phases":2754,"primaryCompletion":344,"completion":369,"start":370,"enrollment":12,"conditions":2755,"interventions":2756},[86],[372],[217,152,374,153,140,142,143,144,146,375,148,317,336,294,376],{"nctId":378,"briefTitle":379,"status":201,"phases":2758,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2759,"interventions":2760},[85,86],[385],[183,149,387,388,389,374,390,391,392,393,317,140,141,142,143,144,145,146,336],{"nctId":220,"briefTitle":221,"status":201,"phases":2762,"primaryCompletion":223,"completion":223,"start":224,"enrollment":12,"conditions":2763,"interventions":2764},[85,86],[226,227],[140,144,147,183,150,153,184,155,156,229,230,142,143,145,146,151,44],{"nctId":410,"briefTitle":411,"status":109,"phases":2766,"primaryCompletion":133,"completion":413,"start":414,"enrollment":24,"conditions":2767,"interventions":2768},[85,86],[15],[139,317,140,141,142,143,144,145,146,147,149,150,153,154,155,156,319,148],{"nctId":418,"briefTitle":419,"status":201,"phases":2770,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2771,"interventions":2772},[85,86],[26],[148,170,150,152,153,423,155,156,424,317,142,143,146,336],{"nctId":426,"briefTitle":427,"status":201,"phases":2774,"primaryCompletion":429,"completion":343,"start":430,"enrollment":12,"conditions":2775,"interventions":2776},[86],[432],[155,184,139,156,140,142,143,144,145,146,148,317,336,153,434,435],{"nctId":841,"briefTitle":842,"status":201,"phases":2778,"primaryCompletion":381,"completion":382,"start":844,"enrollment":12,"conditions":2779,"interventions":2780},[85,86],[846],[183,170,150,152,389,184,390,391,848,443,393,319,317,140,141,142,143,144,145,146,336],{"nctId":850,"briefTitle":851,"status":201,"phases":2782,"primaryCompletion":381,"completion":382,"start":344,"enrollment":12,"conditions":2783,"interventions":2784},[85,86],[854],[183,149,387,856,153,184,390,391,848,443,393,857,317,140,141,142,143,144,145,146,336],{"nctId":437,"briefTitle":438,"status":201,"phases":2786,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2787,"interventions":2788},[85,86],[441],[148,170,150,151,152,389,184,390,391,392,443,393,317,140,141,142,143,144,145,146,336],{"nctId":453,"briefTitle":454,"status":201,"phases":2790,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2791,"interventions":2792},[85,86],[181],[183,149,387,388,389,184,155,392,393,317,140,142,143,144,145,146,336],{"nctId":459,"briefTitle":460,"status":201,"phases":2794,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2795,"interventions":2796},[85,86],[463],[148,170,150,152,153,423,155,392,465,424,317,140,142,143,145,146,336],{"trials":2798,"activeCount":12},[],{"trials":2800,"activeCount":12},[],{"trials":2802,"activeCount":12},[],{"intervention":140,"totalTrials":92,"cells":2804},{"EARLY_PHASE1":2805,"PHASE1":2807,"PHASE2":2809,"PHASE3":2879,"PHASE4":2881,"NA":2883},{"trials":2806,"activeCount":12},[],{"trials":2808,"activeCount":12},[],{"trials":2810,"activeCount":12},[2811,2815,2819,2823,2827,2831,2835,2839,2843,2847,2851,2855,2859,2863,2867,2871,2875],{"nctId":309,"briefTitle":310,"status":109,"phases":2812,"primaryCompletion":312,"completion":313,"start":314,"enrollment":19,"conditions":2813,"interventions":2814},[85,86],[15],[139,317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":130,"briefTitle":131,"status":109,"phases":2816,"primaryCompletion":133,"completion":134,"start":135,"enrollment":19,"conditions":2817,"interventions":2818},[85,86],[137],[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,44],{"nctId":325,"briefTitle":326,"status":109,"phases":2820,"primaryCompletion":328,"completion":329,"start":330,"enrollment":33,"conditions":2821,"interventions":2822},[85,86],[332,333],[335,317,140,141,142,143,144,145,146,336,148,150,151,153,184,155,217,319,337],{"nctId":339,"briefTitle":340,"status":201,"phases":2824,"primaryCompletion":342,"completion":343,"start":344,"enrollment":12,"conditions":2825,"interventions":2826},[86],[346],[77,217,139,317,140,141,142,143,144,145,146,336,148,170,150,153,184,155,319],{"nctId":173,"briefTitle":174,"status":109,"phases":2828,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":2829,"interventions":2830},[85,86],[181],[139,44,140,142,143,144,145,146,147,183,149,150,152,153,184,155,156],{"nctId":353,"briefTitle":354,"status":109,"phases":2832,"primaryCompletion":356,"completion":357,"start":358,"enrollment":16,"conditions":2833,"interventions":2834},[85,86],[15],[317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":366,"briefTitle":367,"status":201,"phases":2836,"primaryCompletion":344,"completion":369,"start":370,"enrollment":12,"conditions":2837,"interventions":2838},[86],[372],[217,152,374,153,140,142,143,144,146,375,148,317,336,294,376],{"nctId":378,"briefTitle":379,"status":201,"phases":2840,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2841,"interventions":2842},[85,86],[385],[183,149,387,388,389,374,390,391,392,393,317,140,141,142,143,144,145,146,336],{"nctId":220,"briefTitle":221,"status":201,"phases":2844,"primaryCompletion":223,"completion":223,"start":224,"enrollment":12,"conditions":2845,"interventions":2846},[85,86],[226,227],[140,144,147,183,150,153,184,155,156,229,230,142,143,145,146,151,44],{"nctId":410,"briefTitle":411,"status":109,"phases":2848,"primaryCompletion":133,"completion":413,"start":414,"enrollment":24,"conditions":2849,"interventions":2850},[85,86],[15],[139,317,140,141,142,143,144,145,146,147,149,150,153,154,155,156,319,148],{"nctId":426,"briefTitle":427,"status":201,"phases":2852,"primaryCompletion":429,"completion":343,"start":430,"enrollment":12,"conditions":2853,"interventions":2854},[86],[432],[155,184,139,156,140,142,143,144,145,146,148,317,336,153,434,435],{"nctId":841,"briefTitle":842,"status":201,"phases":2856,"primaryCompletion":381,"completion":382,"start":844,"enrollment":12,"conditions":2857,"interventions":2858},[85,86],[846],[183,170,150,152,389,184,390,391,848,443,393,319,317,140,141,142,143,144,145,146,336],{"nctId":850,"briefTitle":851,"status":201,"phases":2860,"primaryCompletion":381,"completion":382,"start":344,"enrollment":12,"conditions":2861,"interventions":2862},[85,86],[854],[183,149,387,856,153,184,390,391,848,443,393,857,317,140,141,142,143,144,145,146,336],{"nctId":437,"briefTitle":438,"status":201,"phases":2864,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2865,"interventions":2866},[85,86],[441],[148,170,150,151,152,389,184,390,391,392,443,393,317,140,141,142,143,144,145,146,336],{"nctId":453,"briefTitle":454,"status":201,"phases":2868,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2869,"interventions":2870},[85,86],[181],[183,149,387,388,389,184,155,392,393,317,140,142,143,144,145,146,336],{"nctId":459,"briefTitle":460,"status":201,"phases":2872,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2873,"interventions":2874},[85,86],[463],[148,170,150,152,153,423,155,392,465,424,317,140,142,143,145,146,336],{"nctId":467,"briefTitle":468,"status":109,"phases":2876,"primaryCompletion":470,"completion":357,"start":471,"enrollment":24,"conditions":2877,"interventions":2878},[85,86],[15],[153,319,150,184,155,392,149,183,317,474,140,144],{"trials":2880,"activeCount":12},[],{"trials":2882,"activeCount":12},[],{"trials":2884,"activeCount":12},[],{"intervention":144,"totalTrials":92,"cells":2886},{"EARLY_PHASE1":2887,"PHASE1":2889,"PHASE2":2891,"PHASE3":2961,"PHASE4":2963,"NA":2965},{"trials":2888,"activeCount":12},[],{"trials":2890,"activeCount":12},[],{"trials":2892,"activeCount":12},[2893,2897,2901,2905,2909,2913,2917,2921,2925,2929,2933,2937,2941,2945,2949,2953,2957],{"nctId":309,"briefTitle":310,"status":109,"phases":2894,"primaryCompletion":312,"completion":313,"start":314,"enrollment":19,"conditions":2895,"interventions":2896},[85,86],[15],[139,317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":130,"briefTitle":131,"status":109,"phases":2898,"primaryCompletion":133,"completion":134,"start":135,"enrollment":19,"conditions":2899,"interventions":2900},[85,86],[137],[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,44],{"nctId":325,"briefTitle":326,"status":109,"phases":2902,"primaryCompletion":328,"completion":329,"start":330,"enrollment":33,"conditions":2903,"interventions":2904},[85,86],[332,333],[335,317,140,141,142,143,144,145,146,336,148,150,151,153,184,155,217,319,337],{"nctId":339,"briefTitle":340,"status":201,"phases":2906,"primaryCompletion":342,"completion":343,"start":344,"enrollment":12,"conditions":2907,"interventions":2908},[86],[346],[77,217,139,317,140,141,142,143,144,145,146,336,148,170,150,153,184,155,319],{"nctId":173,"briefTitle":174,"status":109,"phases":2910,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":2911,"interventions":2912},[85,86],[181],[139,44,140,142,143,144,145,146,147,183,149,150,152,153,184,155,156],{"nctId":797,"briefTitle":798,"status":201,"phases":2914,"primaryCompletion":800,"completion":382,"start":383,"enrollment":12,"conditions":2915,"interventions":2916},[85,86],[802],[148,170,150,153,423,804,155,805,806,319,317,141,142,143,144,146,807],{"nctId":353,"briefTitle":354,"status":109,"phases":2918,"primaryCompletion":356,"completion":357,"start":358,"enrollment":16,"conditions":2919,"interventions":2920},[85,86],[15],[317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":366,"briefTitle":367,"status":201,"phases":2922,"primaryCompletion":344,"completion":369,"start":370,"enrollment":12,"conditions":2923,"interventions":2924},[86],[372],[217,152,374,153,140,142,143,144,146,375,148,317,336,294,376],{"nctId":378,"briefTitle":379,"status":201,"phases":2926,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2927,"interventions":2928},[85,86],[385],[183,149,387,388,389,374,390,391,392,393,317,140,141,142,143,144,145,146,336],{"nctId":220,"briefTitle":221,"status":201,"phases":2930,"primaryCompletion":223,"completion":223,"start":224,"enrollment":12,"conditions":2931,"interventions":2932},[85,86],[226,227],[140,144,147,183,150,153,184,155,156,229,230,142,143,145,146,151,44],{"nctId":410,"briefTitle":411,"status":109,"phases":2934,"primaryCompletion":133,"completion":413,"start":414,"enrollment":24,"conditions":2935,"interventions":2936},[85,86],[15],[139,317,140,141,142,143,144,145,146,147,149,150,153,154,155,156,319,148],{"nctId":426,"briefTitle":427,"status":201,"phases":2938,"primaryCompletion":429,"completion":343,"start":430,"enrollment":12,"conditions":2939,"interventions":2940},[86],[432],[155,184,139,156,140,142,143,144,145,146,148,317,336,153,434,435],{"nctId":841,"briefTitle":842,"status":201,"phases":2942,"primaryCompletion":381,"completion":382,"start":844,"enrollment":12,"conditions":2943,"interventions":2944},[85,86],[846],[183,170,150,152,389,184,390,391,848,443,393,319,317,140,141,142,143,144,145,146,336],{"nctId":850,"briefTitle":851,"status":201,"phases":2946,"primaryCompletion":381,"completion":382,"start":344,"enrollment":12,"conditions":2947,"interventions":2948},[85,86],[854],[183,149,387,856,153,184,390,391,848,443,393,857,317,140,141,142,143,144,145,146,336],{"nctId":437,"briefTitle":438,"status":201,"phases":2950,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2951,"interventions":2952},[85,86],[441],[148,170,150,151,152,389,184,390,391,392,443,393,317,140,141,142,143,144,145,146,336],{"nctId":453,"briefTitle":454,"status":201,"phases":2954,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2955,"interventions":2956},[85,86],[181],[183,149,387,388,389,184,155,392,393,317,140,142,143,144,145,146,336],{"nctId":467,"briefTitle":468,"status":109,"phases":2958,"primaryCompletion":470,"completion":357,"start":471,"enrollment":24,"conditions":2959,"interventions":2960},[85,86],[15],[153,319,150,184,155,392,149,183,317,474,140,144],{"trials":2962,"activeCount":12},[],{"trials":2964,"activeCount":12},[],{"trials":2966,"activeCount":12},[],{"intervention":336,"totalTrials":2968,"cells":2969},13,{"EARLY_PHASE1":2970,"PHASE1":2972,"PHASE2":2974,"PHASE3":3028,"PHASE4":3030,"NA":3032},{"trials":2971,"activeCount":12},[],{"trials":2973,"activeCount":12},[],{"trials":2975,"activeCount":12},[2976,2980,2984,2988,2992,2996,3000,3004,3008,3012,3016,3020,3024],{"nctId":767,"briefTitle":768,"status":201,"phases":2977,"primaryCompletion":770,"completion":382,"start":771,"enrollment":12,"conditions":2978,"interventions":2979},[85,86],[773,774],[335,317,142,143,146,336,148,151,153],{"nctId":325,"briefTitle":326,"status":109,"phases":2981,"primaryCompletion":328,"completion":329,"start":330,"enrollment":33,"conditions":2982,"interventions":2983},[85,86],[332,333],[335,317,140,141,142,143,144,145,146,336,148,150,151,153,184,155,217,319,337],{"nctId":339,"briefTitle":340,"status":201,"phases":2985,"primaryCompletion":342,"completion":343,"start":344,"enrollment":12,"conditions":2986,"interventions":2987},[86],[346],[77,217,139,317,140,141,142,143,144,145,146,336,148,170,150,153,184,155,319],{"nctId":366,"briefTitle":367,"status":201,"phases":2989,"primaryCompletion":344,"completion":369,"start":370,"enrollment":12,"conditions":2990,"interventions":2991},[86],[372],[217,152,374,153,140,142,143,144,146,375,148,317,336,294,376],{"nctId":378,"briefTitle":379,"status":201,"phases":2993,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2994,"interventions":2995},[85,86],[385],[183,149,387,388,389,374,390,391,392,393,317,140,141,142,143,144,145,146,336],{"nctId":418,"briefTitle":419,"status":201,"phases":2997,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":2998,"interventions":2999},[85,86],[26],[148,170,150,152,153,423,155,156,424,317,142,143,146,336],{"nctId":426,"briefTitle":427,"status":201,"phases":3001,"primaryCompletion":429,"completion":343,"start":430,"enrollment":12,"conditions":3002,"interventions":3003},[86],[432],[155,184,139,156,140,142,143,144,145,146,148,317,336,153,434,435],{"nctId":841,"briefTitle":842,"status":201,"phases":3005,"primaryCompletion":381,"completion":382,"start":844,"enrollment":12,"conditions":3006,"interventions":3007},[85,86],[846],[183,170,150,152,389,184,390,391,848,443,393,319,317,140,141,142,143,144,145,146,336],{"nctId":850,"briefTitle":851,"status":201,"phases":3009,"primaryCompletion":381,"completion":382,"start":344,"enrollment":12,"conditions":3010,"interventions":3011},[85,86],[854],[183,149,387,856,153,184,390,391,848,443,393,857,317,140,141,142,143,144,145,146,336],{"nctId":437,"briefTitle":438,"status":201,"phases":3013,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3014,"interventions":3015},[85,86],[441],[148,170,150,151,152,389,184,390,391,392,443,393,317,140,141,142,143,144,145,146,336],{"nctId":445,"briefTitle":446,"status":201,"phases":3017,"primaryCompletion":381,"completion":448,"start":383,"enrollment":12,"conditions":3018,"interventions":3019},[85,86],[450],[183,149,387,389,184,391,392,393,319,197,317,143,336],{"nctId":453,"briefTitle":454,"status":201,"phases":3021,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3022,"interventions":3023},[85,86],[181],[183,149,387,388,389,184,155,392,393,317,140,142,143,144,145,146,336],{"nctId":459,"briefTitle":460,"status":201,"phases":3025,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3026,"interventions":3027},[85,86],[463],[148,170,150,152,153,423,155,392,465,424,317,140,142,143,145,146,336],{"trials":3029,"activeCount":12},[],{"trials":3031,"activeCount":12},[],{"trials":3033,"activeCount":12},[],{"intervention":145,"totalTrials":2968,"cells":3035},{"EARLY_PHASE1":3036,"PHASE1":3038,"PHASE2":3040,"PHASE3":3094,"PHASE4":3096,"NA":3098},{"trials":3037,"activeCount":12},[],{"trials":3039,"activeCount":12},[],{"trials":3041,"activeCount":12},[3042,3046,3050,3054,3058,3062,3066,3070,3074,3078,3082,3086,3090],{"nctId":130,"briefTitle":131,"status":109,"phases":3043,"primaryCompletion":133,"completion":134,"start":135,"enrollment":19,"conditions":3044,"interventions":3045},[85,86],[137],[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,44],{"nctId":325,"briefTitle":326,"status":109,"phases":3047,"primaryCompletion":328,"completion":329,"start":330,"enrollment":33,"conditions":3048,"interventions":3049},[85,86],[332,333],[335,317,140,141,142,143,144,145,146,336,148,150,151,153,184,155,217,319,337],{"nctId":339,"briefTitle":340,"status":201,"phases":3051,"primaryCompletion":342,"completion":343,"start":344,"enrollment":12,"conditions":3052,"interventions":3053},[86],[346],[77,217,139,317,140,141,142,143,144,145,146,336,148,170,150,153,184,155,319],{"nctId":173,"briefTitle":174,"status":109,"phases":3055,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":3056,"interventions":3057},[85,86],[181],[139,44,140,142,143,144,145,146,147,183,149,150,152,153,184,155,156],{"nctId":378,"briefTitle":379,"status":201,"phases":3059,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3060,"interventions":3061},[85,86],[385],[183,149,387,388,389,374,390,391,392,393,317,140,141,142,143,144,145,146,336],{"nctId":220,"briefTitle":221,"status":201,"phases":3063,"primaryCompletion":223,"completion":223,"start":224,"enrollment":12,"conditions":3064,"interventions":3065},[85,86],[226,227],[140,144,147,183,150,153,184,155,156,229,230,142,143,145,146,151,44],{"nctId":410,"briefTitle":411,"status":109,"phases":3067,"primaryCompletion":133,"completion":413,"start":414,"enrollment":24,"conditions":3068,"interventions":3069},[85,86],[15],[139,317,140,141,142,143,144,145,146,147,149,150,153,154,155,156,319,148],{"nctId":426,"briefTitle":427,"status":201,"phases":3071,"primaryCompletion":429,"completion":343,"start":430,"enrollment":12,"conditions":3072,"interventions":3073},[86],[432],[155,184,139,156,140,142,143,144,145,146,148,317,336,153,434,435],{"nctId":841,"briefTitle":842,"status":201,"phases":3075,"primaryCompletion":381,"completion":382,"start":844,"enrollment":12,"conditions":3076,"interventions":3077},[85,86],[846],[183,170,150,152,389,184,390,391,848,443,393,319,317,140,141,142,143,144,145,146,336],{"nctId":850,"briefTitle":851,"status":201,"phases":3079,"primaryCompletion":381,"completion":382,"start":344,"enrollment":12,"conditions":3080,"interventions":3081},[85,86],[854],[183,149,387,856,153,184,390,391,848,443,393,857,317,140,141,142,143,144,145,146,336],{"nctId":437,"briefTitle":438,"status":201,"phases":3083,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3084,"interventions":3085},[85,86],[441],[148,170,150,151,152,389,184,390,391,392,443,393,317,140,141,142,143,144,145,146,336],{"nctId":453,"briefTitle":454,"status":201,"phases":3087,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3088,"interventions":3089},[85,86],[181],[183,149,387,388,389,184,155,392,393,317,140,142,143,144,145,146,336],{"nctId":459,"briefTitle":460,"status":201,"phases":3091,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3092,"interventions":3093},[85,86],[463],[148,170,150,152,153,423,155,392,465,424,317,140,142,143,145,146,336],{"trials":3095,"activeCount":12},[],{"trials":3097,"activeCount":12},[],{"trials":3099,"activeCount":12},[],{"intervention":319,"totalTrials":123,"cells":3101},{"EARLY_PHASE1":3102,"PHASE1":3104,"PHASE2":3106,"PHASE3":3148,"PHASE4":3150,"NA":3152},{"trials":3103,"activeCount":12},[],{"trials":3105,"activeCount":12},[],{"trials":3107,"activeCount":12},[3108,3112,3116,3120,3124,3128,3132,3136,3140,3144],{"nctId":309,"briefTitle":310,"status":109,"phases":3109,"primaryCompletion":312,"completion":313,"start":314,"enrollment":19,"conditions":3110,"interventions":3111},[85,86],[15],[139,317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":325,"briefTitle":326,"status":109,"phases":3113,"primaryCompletion":328,"completion":329,"start":330,"enrollment":33,"conditions":3114,"interventions":3115},[85,86],[332,333],[335,317,140,141,142,143,144,145,146,336,148,150,151,153,184,155,217,319,337],{"nctId":339,"briefTitle":340,"status":201,"phases":3117,"primaryCompletion":342,"completion":343,"start":344,"enrollment":12,"conditions":3118,"interventions":3119},[86],[346],[77,217,139,317,140,141,142,143,144,145,146,336,148,170,150,153,184,155,319],{"nctId":797,"briefTitle":798,"status":201,"phases":3121,"primaryCompletion":800,"completion":382,"start":383,"enrollment":12,"conditions":3122,"interventions":3123},[85,86],[802],[148,170,150,153,423,804,155,805,806,319,317,141,142,143,144,146,807],{"nctId":353,"briefTitle":354,"status":109,"phases":3125,"primaryCompletion":356,"completion":357,"start":358,"enrollment":16,"conditions":3126,"interventions":3127},[85,86],[15],[317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":410,"briefTitle":411,"status":109,"phases":3129,"primaryCompletion":133,"completion":413,"start":414,"enrollment":24,"conditions":3130,"interventions":3131},[85,86],[15],[139,317,140,141,142,143,144,145,146,147,149,150,153,154,155,156,319,148],{"nctId":841,"briefTitle":842,"status":201,"phases":3133,"primaryCompletion":381,"completion":382,"start":844,"enrollment":12,"conditions":3134,"interventions":3135},[85,86],[846],[183,170,150,152,389,184,390,391,848,443,393,319,317,140,141,142,143,144,145,146,336],{"nctId":850,"briefTitle":851,"status":201,"phases":3137,"primaryCompletion":381,"completion":382,"start":344,"enrollment":12,"conditions":3138,"interventions":3139},[85,86],[854],[183,149,387,856,153,184,390,391,848,443,393,857,317,140,141,142,143,144,145,146,336],{"nctId":445,"briefTitle":446,"status":201,"phases":3141,"primaryCompletion":381,"completion":448,"start":383,"enrollment":12,"conditions":3142,"interventions":3143},[85,86],[450],[183,149,387,389,184,391,392,393,319,197,317,143,336],{"nctId":467,"briefTitle":468,"status":109,"phases":3145,"primaryCompletion":470,"completion":357,"start":471,"enrollment":24,"conditions":3146,"interventions":3147},[85,86],[15],[153,319,150,184,155,392,149,183,317,474,140,144],{"trials":3149,"activeCount":12},[],{"trials":3151,"activeCount":12},[],{"trials":3153,"activeCount":12},[],{"intervention":141,"totalTrials":179,"cells":3155},{"EARLY_PHASE1":3156,"PHASE1":3158,"PHASE2":3160,"PHASE3":3198,"PHASE4":3200,"NA":3202},{"trials":3157,"activeCount":12},[],{"trials":3159,"activeCount":12},[],{"trials":3161,"activeCount":12},[3162,3166,3170,3174,3178,3182,3186,3190,3194],{"nctId":130,"briefTitle":131,"status":109,"phases":3163,"primaryCompletion":133,"completion":134,"start":135,"enrollment":19,"conditions":3164,"interventions":3165},[85,86],[137],[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,44],{"nctId":325,"briefTitle":326,"status":109,"phases":3167,"primaryCompletion":328,"completion":329,"start":330,"enrollment":33,"conditions":3168,"interventions":3169},[85,86],[332,333],[335,317,140,141,142,143,144,145,146,336,148,150,151,153,184,155,217,319,337],{"nctId":339,"briefTitle":340,"status":201,"phases":3171,"primaryCompletion":342,"completion":343,"start":344,"enrollment":12,"conditions":3172,"interventions":3173},[86],[346],[77,217,139,317,140,141,142,143,144,145,146,336,148,170,150,153,184,155,319],{"nctId":797,"briefTitle":798,"status":201,"phases":3175,"primaryCompletion":800,"completion":382,"start":383,"enrollment":12,"conditions":3176,"interventions":3177},[85,86],[802],[148,170,150,153,423,804,155,805,806,319,317,141,142,143,144,146,807],{"nctId":378,"briefTitle":379,"status":201,"phases":3179,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3180,"interventions":3181},[85,86],[385],[183,149,387,388,389,374,390,391,392,393,317,140,141,142,143,144,145,146,336],{"nctId":410,"briefTitle":411,"status":109,"phases":3183,"primaryCompletion":133,"completion":413,"start":414,"enrollment":24,"conditions":3184,"interventions":3185},[85,86],[15],[139,317,140,141,142,143,144,145,146,147,149,150,153,154,155,156,319,148],{"nctId":841,"briefTitle":842,"status":201,"phases":3187,"primaryCompletion":381,"completion":382,"start":844,"enrollment":12,"conditions":3188,"interventions":3189},[85,86],[846],[183,170,150,152,389,184,390,391,848,443,393,319,317,140,141,142,143,144,145,146,336],{"nctId":850,"briefTitle":851,"status":201,"phases":3191,"primaryCompletion":381,"completion":382,"start":344,"enrollment":12,"conditions":3192,"interventions":3193},[85,86],[854],[183,149,387,856,153,184,390,391,848,443,393,857,317,140,141,142,143,144,145,146,336],{"nctId":437,"briefTitle":438,"status":201,"phases":3195,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3196,"interventions":3197},[85,86],[441],[148,170,150,151,152,389,184,390,391,392,443,393,317,140,141,142,143,144,145,146,336],{"trials":3199,"activeCount":12},[],{"trials":3201,"activeCount":12},[],{"trials":3203,"activeCount":12},[],{"intervention":152,"totalTrials":179,"cells":3205},{"EARLY_PHASE1":3206,"PHASE1":3208,"PHASE2":3210,"PHASE3":3248,"PHASE4":3250,"NA":3252},{"trials":3207,"activeCount":12},[],{"trials":3209,"activeCount":12},[],{"trials":3211,"activeCount":12},[3212,3216,3220,3224,3228,3232,3236,3240,3244],{"nctId":130,"briefTitle":131,"status":109,"phases":3213,"primaryCompletion":133,"completion":134,"start":135,"enrollment":19,"conditions":3214,"interventions":3215},[85,86],[137],[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,44],{"nctId":173,"briefTitle":174,"status":109,"phases":3217,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":3218,"interventions":3219},[85,86],[181],[139,44,140,142,143,144,145,146,147,183,149,150,152,153,184,155,156],{"nctId":366,"briefTitle":367,"status":201,"phases":3221,"primaryCompletion":344,"completion":369,"start":370,"enrollment":12,"conditions":3222,"interventions":3223},[86],[372],[217,152,374,153,140,142,143,144,146,375,148,317,336,294,376],{"nctId":378,"briefTitle":379,"status":201,"phases":3225,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3226,"interventions":3227},[85,86],[385],[183,149,387,388,389,374,390,391,392,393,317,140,141,142,143,144,145,146,336],{"nctId":418,"briefTitle":419,"status":201,"phases":3229,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3230,"interventions":3231},[85,86],[26],[148,170,150,152,153,423,155,156,424,317,142,143,146,336],{"nctId":841,"briefTitle":842,"status":201,"phases":3233,"primaryCompletion":381,"completion":382,"start":844,"enrollment":12,"conditions":3234,"interventions":3235},[85,86],[846],[183,170,150,152,389,184,390,391,848,443,393,319,317,140,141,142,143,144,145,146,336],{"nctId":437,"briefTitle":438,"status":201,"phases":3237,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3238,"interventions":3239},[85,86],[441],[148,170,150,151,152,389,184,390,391,392,443,393,317,140,141,142,143,144,145,146,336],{"nctId":453,"briefTitle":454,"status":201,"phases":3241,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3242,"interventions":3243},[85,86],[181],[183,149,387,388,389,184,155,392,393,317,140,142,143,144,145,146,336],{"nctId":459,"briefTitle":460,"status":201,"phases":3245,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3246,"interventions":3247},[85,86],[463],[148,170,150,152,153,423,155,392,465,424,317,140,142,143,145,146,336],{"trials":3249,"activeCount":12},[],{"trials":3251,"activeCount":12},[],{"trials":3253,"activeCount":12},[],{"intervention":393,"totalTrials":9,"cells":3255},{"EARLY_PHASE1":3256,"PHASE1":3258,"PHASE2":3260,"PHASE3":3294,"PHASE4":3296,"NA":3298},{"trials":3257,"activeCount":12},[],{"trials":3259,"activeCount":12},[],{"trials":3261,"activeCount":12},[3262,3266,3270,3274,3278,3282,3286,3290],{"nctId":309,"briefTitle":310,"status":109,"phases":3263,"primaryCompletion":312,"completion":313,"start":314,"enrollment":19,"conditions":3264,"interventions":3265},[85,86],[15],[139,317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":353,"briefTitle":354,"status":109,"phases":3267,"primaryCompletion":356,"completion":357,"start":358,"enrollment":16,"conditions":3268,"interventions":3269},[85,86],[15],[317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":378,"briefTitle":379,"status":201,"phases":3271,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3272,"interventions":3273},[85,86],[385],[183,149,387,388,389,374,390,391,392,393,317,140,141,142,143,144,145,146,336],{"nctId":841,"briefTitle":842,"status":201,"phases":3275,"primaryCompletion":381,"completion":382,"start":844,"enrollment":12,"conditions":3276,"interventions":3277},[85,86],[846],[183,170,150,152,389,184,390,391,848,443,393,319,317,140,141,142,143,144,145,146,336],{"nctId":850,"briefTitle":851,"status":201,"phases":3279,"primaryCompletion":381,"completion":382,"start":344,"enrollment":12,"conditions":3280,"interventions":3281},[85,86],[854],[183,149,387,856,153,184,390,391,848,443,393,857,317,140,141,142,143,144,145,146,336],{"nctId":437,"briefTitle":438,"status":201,"phases":3283,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3284,"interventions":3285},[85,86],[441],[148,170,150,151,152,389,184,390,391,392,443,393,317,140,141,142,143,144,145,146,336],{"nctId":445,"briefTitle":446,"status":201,"phases":3287,"primaryCompletion":381,"completion":448,"start":383,"enrollment":12,"conditions":3288,"interventions":3289},[85,86],[450],[183,149,387,389,184,391,392,393,319,197,317,143,336],{"nctId":453,"briefTitle":454,"status":201,"phases":3291,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3292,"interventions":3293},[85,86],[181],[183,149,387,388,389,184,155,392,393,317,140,142,143,144,145,146,336],{"trials":3295,"activeCount":12},[],{"trials":3297,"activeCount":12},[],{"trials":3299,"activeCount":12},[],{"intervention":151,"totalTrials":16,"cells":3301},{"EARLY_PHASE1":3302,"PHASE1":3304,"PHASE2":3306,"PHASE3":3332,"PHASE4":3334,"NA":3336},{"trials":3303,"activeCount":12},[],{"trials":3305,"activeCount":12},[],{"trials":3307,"activeCount":12},[3308,3312,3316,3320,3324,3328],{"nctId":767,"briefTitle":768,"status":201,"phases":3309,"primaryCompletion":770,"completion":382,"start":771,"enrollment":12,"conditions":3310,"interventions":3311},[85,86],[773,774],[335,317,142,143,146,336,148,151,153],{"nctId":130,"briefTitle":131,"status":109,"phases":3313,"primaryCompletion":133,"completion":134,"start":135,"enrollment":19,"conditions":3314,"interventions":3315},[85,86],[137],[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,44],{"nctId":325,"briefTitle":326,"status":109,"phases":3317,"primaryCompletion":328,"completion":329,"start":330,"enrollment":33,"conditions":3318,"interventions":3319},[85,86],[332,333],[335,317,140,141,142,143,144,145,146,336,148,150,151,153,184,155,217,319,337],{"nctId":220,"briefTitle":221,"status":201,"phases":3321,"primaryCompletion":223,"completion":223,"start":224,"enrollment":12,"conditions":3322,"interventions":3323},[85,86],[226,227],[140,144,147,183,150,153,184,155,156,229,230,142,143,145,146,151,44],{"nctId":850,"briefTitle":851,"status":201,"phases":3325,"primaryCompletion":381,"completion":382,"start":344,"enrollment":12,"conditions":3326,"interventions":3327},[85,86],[854],[183,149,387,856,153,184,390,391,848,443,393,857,317,140,141,142,143,144,145,146,336],{"nctId":437,"briefTitle":438,"status":201,"phases":3329,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3330,"interventions":3331},[85,86],[441],[148,170,150,151,152,389,184,390,391,392,443,393,317,140,141,142,143,144,145,146,336],{"trials":3333,"activeCount":12},[],{"trials":3335,"activeCount":12},[],{"trials":3337,"activeCount":12},[],{"intervention":147,"totalTrials":16,"cells":3339},{"EARLY_PHASE1":3340,"PHASE1":3342,"PHASE2":3344,"PHASE3":3370,"PHASE4":3372,"NA":3374},{"trials":3341,"activeCount":12},[],{"trials":3343,"activeCount":12},[],{"trials":3345,"activeCount":12},[3346,3350,3354,3358,3362,3366],{"nctId":309,"briefTitle":310,"status":109,"phases":3347,"primaryCompletion":312,"completion":313,"start":314,"enrollment":19,"conditions":3348,"interventions":3349},[85,86],[15],[139,317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":130,"briefTitle":131,"status":109,"phases":3351,"primaryCompletion":133,"completion":134,"start":135,"enrollment":19,"conditions":3352,"interventions":3353},[85,86],[137],[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,44],{"nctId":173,"briefTitle":174,"status":109,"phases":3355,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":3356,"interventions":3357},[85,86],[181],[139,44,140,142,143,144,145,146,147,183,149,150,152,153,184,155,156],{"nctId":353,"briefTitle":354,"status":109,"phases":3359,"primaryCompletion":356,"completion":357,"start":358,"enrollment":16,"conditions":3360,"interventions":3361},[85,86],[15],[317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":220,"briefTitle":221,"status":201,"phases":3363,"primaryCompletion":223,"completion":223,"start":224,"enrollment":12,"conditions":3364,"interventions":3365},[85,86],[226,227],[140,144,147,183,150,153,184,155,156,229,230,142,143,145,146,151,44],{"nctId":410,"briefTitle":411,"status":109,"phases":3367,"primaryCompletion":133,"completion":413,"start":414,"enrollment":24,"conditions":3368,"interventions":3369},[85,86],[15],[139,317,140,141,142,143,144,145,146,147,149,150,153,154,155,156,319,148],{"trials":3371,"activeCount":12},[],{"trials":3373,"activeCount":12},[],{"trials":3375,"activeCount":12},[],{"intervention":390,"totalTrials":271,"cells":3377},{"EARLY_PHASE1":3378,"PHASE1":3380,"PHASE2":3382,"PHASE3":3404,"PHASE4":3406,"NA":3408},{"trials":3379,"activeCount":12},[],{"trials":3381,"activeCount":12},[],{"trials":3383,"activeCount":12},[3384,3388,3392,3396,3400],{"nctId":797,"briefTitle":798,"status":201,"phases":3385,"primaryCompletion":800,"completion":382,"start":383,"enrollment":12,"conditions":3386,"interventions":3387},[85,86],[802],[148,170,150,153,423,804,155,805,806,319,317,141,142,143,144,146,807],{"nctId":378,"briefTitle":379,"status":201,"phases":3389,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3390,"interventions":3391},[85,86],[385],[183,149,387,388,389,374,390,391,392,393,317,140,141,142,143,144,145,146,336],{"nctId":841,"briefTitle":842,"status":201,"phases":3393,"primaryCompletion":381,"completion":382,"start":844,"enrollment":12,"conditions":3394,"interventions":3395},[85,86],[846],[183,170,150,152,389,184,390,391,848,443,393,319,317,140,141,142,143,144,145,146,336],{"nctId":850,"briefTitle":851,"status":201,"phases":3397,"primaryCompletion":381,"completion":382,"start":344,"enrollment":12,"conditions":3398,"interventions":3399},[85,86],[854],[183,149,387,856,153,184,390,391,848,443,393,857,317,140,141,142,143,144,145,146,336],{"nctId":437,"briefTitle":438,"status":201,"phases":3401,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3402,"interventions":3403},[85,86],[441],[148,170,150,151,152,389,184,390,391,392,443,393,317,140,141,142,143,144,145,146,336],{"trials":3405,"activeCount":12},[],{"trials":3407,"activeCount":12},[],{"trials":3409,"activeCount":12},[],{"intervention":154,"totalTrials":19,"cells":3411},{"EARLY_PHASE1":3412,"PHASE1":3414,"PHASE2":3416,"PHASE3":3434,"PHASE4":3436,"NA":3438},{"trials":3413,"activeCount":12},[],{"trials":3415,"activeCount":12},[],{"trials":3417,"activeCount":12},[3418,3422,3426,3430],{"nctId":309,"briefTitle":310,"status":109,"phases":3419,"primaryCompletion":312,"completion":313,"start":314,"enrollment":19,"conditions":3420,"interventions":3421},[85,86],[15],[139,317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":130,"briefTitle":131,"status":109,"phases":3423,"primaryCompletion":133,"completion":134,"start":135,"enrollment":19,"conditions":3424,"interventions":3425},[85,86],[137],[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,44],{"nctId":353,"briefTitle":354,"status":109,"phases":3427,"primaryCompletion":356,"completion":357,"start":358,"enrollment":16,"conditions":3428,"interventions":3429},[85,86],[15],[317,140,144,147,183,149,150,153,154,155,156,318,319],{"nctId":410,"briefTitle":411,"status":109,"phases":3431,"primaryCompletion":133,"completion":413,"start":414,"enrollment":24,"conditions":3432,"interventions":3433},[85,86],[15],[139,317,140,141,142,143,144,145,146,147,149,150,153,154,155,156,319,148],{"trials":3435,"activeCount":12},[],{"trials":3437,"activeCount":12},[],{"trials":3439,"activeCount":12},[],{"intervention":3441,"totalTrials":19,"cells":3442},"hAd5-S-Fusion+N-ETSD vaccine",{"EARLY_PHASE1":3443,"PHASE1":3445,"PHASE2":3465,"PHASE3":3481,"PHASE4":3483,"NA":3485},{"trials":3444,"activeCount":12},[],{"trials":3446,"activeCount":12},[3447,3456],{"nctId":3448,"briefTitle":3449,"status":119,"phases":3450,"primaryCompletion":3451,"completion":3451,"start":3452,"enrollment":3453,"conditions":3454,"interventions":3455},"NCT04710303","COVID-19 Vaccination Using a 2nd Generation (E1\u002FE2B\u002FE3-Deleted) Adenoviral Platform in Healthy South African Adults",[85],"2022-08-02","2021-03-02",41,[21],[3441],{"nctId":3457,"briefTitle":3458,"status":119,"phases":3459,"primaryCompletion":3460,"completion":3461,"start":3462,"enrollment":166,"conditions":3463,"interventions":3464},"NCT04591717","COVID-19 Vaccination Using a 2nd Generation (E1\u002FE2B\u002FE3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers",[85],"2022-04-20","2023-01-18","2020-10-19",[18],[3441],{"trials":3466,"activeCount":12},[3467,3475],{"nctId":3468,"briefTitle":3469,"status":201,"phases":3470,"primaryCompletion":3471,"completion":3472,"start":3471,"enrollment":12,"conditions":3473,"interventions":3474},"NCT04845191","COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines",[85,86],"2021-12","2021-12-14",[21],[3441],{"nctId":3476,"briefTitle":3477,"status":201,"phases":3478,"primaryCompletion":3471,"completion":3472,"start":3471,"enrollment":12,"conditions":3479,"interventions":3480},"NCT04843722","COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines",[85,86],[21],[3441],{"trials":3482,"activeCount":12},[],{"trials":3484,"activeCount":12},[],{"trials":3486,"activeCount":12},[],{"intervention":443,"totalTrials":19,"cells":3488},{"EARLY_PHASE1":3489,"PHASE1":3491,"PHASE2":3493,"PHASE3":3511,"PHASE4":3513,"NA":3515},{"trials":3490,"activeCount":12},[],{"trials":3492,"activeCount":12},[],{"trials":3494,"activeCount":12},[3495,3499,3503,3507],{"nctId":841,"briefTitle":842,"status":201,"phases":3496,"primaryCompletion":381,"completion":382,"start":844,"enrollment":12,"conditions":3497,"interventions":3498},[85,86],[846],[183,170,150,152,389,184,390,391,848,443,393,319,317,140,141,142,143,144,145,146,336],{"nctId":850,"briefTitle":851,"status":201,"phases":3500,"primaryCompletion":381,"completion":382,"start":344,"enrollment":12,"conditions":3501,"interventions":3502},[85,86],[854],[183,149,387,856,153,184,390,391,848,443,393,857,317,140,141,142,143,144,145,146,336],{"nctId":437,"briefTitle":438,"status":201,"phases":3504,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3505,"interventions":3506},[85,86],[441],[148,170,150,151,152,389,184,390,391,392,443,393,317,140,141,142,143,144,145,146,336],{"nctId":459,"briefTitle":460,"status":201,"phases":3508,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3509,"interventions":3510},[85,86],[463],[148,170,150,152,153,423,155,392,465,424,317,140,142,143,145,146,336],{"trials":3512,"activeCount":12},[],{"trials":3514,"activeCount":12},[],{"trials":3516,"activeCount":12},[],{"intervention":335,"totalTrials":24,"cells":3518},{"EARLY_PHASE1":3519,"PHASE1":3521,"PHASE2":3523,"PHASE3":3537,"PHASE4":3539,"NA":3541},{"trials":3520,"activeCount":12},[],{"trials":3522,"activeCount":12},[],{"trials":3524,"activeCount":12},[3525,3529,3533],{"nctId":767,"briefTitle":768,"status":201,"phases":3526,"primaryCompletion":770,"completion":382,"start":771,"enrollment":12,"conditions":3527,"interventions":3528},[85,86],[773,774],[335,317,142,143,146,336,148,151,153],{"nctId":325,"briefTitle":326,"status":109,"phases":3530,"primaryCompletion":328,"completion":329,"start":330,"enrollment":33,"conditions":3531,"interventions":3532},[85,86],[332,333],[335,317,140,141,142,143,144,145,146,336,148,150,151,153,184,155,217,319,337],{"nctId":220,"briefTitle":221,"status":201,"phases":3534,"primaryCompletion":223,"completion":223,"start":224,"enrollment":12,"conditions":3535,"interventions":3536},[85,86],[226,227],[140,144,147,183,150,153,184,155,156,229,230,142,143,145,146,151,44],{"trials":3538,"activeCount":12},[],{"trials":3540,"activeCount":12},[],{"trials":3542,"activeCount":12},[],{"intervention":3544,"totalTrials":24,"cells":3545},"INNO-206",{"EARLY_PHASE1":3546,"PHASE1":3548,"PHASE2":3560,"PHASE3":3586,"PHASE4":3588,"NA":3590},{"trials":3547,"activeCount":12},[],{"trials":3549,"activeCount":12},[3550],{"nctId":3551,"briefTitle":3552,"status":119,"phases":3553,"primaryCompletion":3554,"completion":3555,"start":3556,"enrollment":748,"conditions":3557,"interventions":3559},"NCT01337505","Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors",[85],"2012-09","2012-12","2011-04",[3558],"Malignant Solid Tumour",[3544],{"trials":3561,"activeCount":12},[3562,3572],{"nctId":3563,"briefTitle":3564,"status":119,"phases":3565,"primaryCompletion":3566,"completion":3567,"start":3568,"enrollment":1224,"conditions":3569,"interventions":3571},"NCT01580397","Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer",[86],"2013-05-13","2013-07-02","2012-05-16",[3570],"Pancreatic Ductal Adenocarcinoma",[3544],{"nctId":3573,"briefTitle":3574,"status":119,"phases":3575,"primaryCompletion":3576,"completion":3577,"start":3578,"enrollment":3579,"conditions":3580,"interventions":3584},"NCT01514188","Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma",[86],"2014-04-09","2014-12-15","2012-01-11",126,[3581,3582,3583],"Metastatic Soft Tissue Sarcoma","Locally Advanced Soft Tissue Sarcoma","Unresectable Soft Tissue Sarcoma",[3544,3585],"Doxorubicin",{"trials":3587,"activeCount":12},[],{"trials":3589,"activeCount":12},[],{"trials":3591,"activeCount":12},[],{"intervention":209,"totalTrials":33,"cells":3593},{"EARLY_PHASE1":3594,"PHASE1":3596,"PHASE2":3598,"PHASE3":3608,"PHASE4":3610,"NA":3612},{"trials":3595,"activeCount":12},[],{"trials":3597,"activeCount":12},[],{"trials":3599,"activeCount":12},[3600,3604],{"nctId":199,"briefTitle":200,"status":201,"phases":3601,"primaryCompletion":203,"completion":204,"start":205,"enrollment":12,"conditions":3602,"interventions":3603},[86],[207],[44,209,210],{"nctId":238,"briefTitle":239,"status":201,"phases":3605,"primaryCompletion":203,"completion":204,"start":241,"enrollment":12,"conditions":3606,"interventions":3607},[86],[207],[44,209,210],{"trials":3609,"activeCount":12},[],{"trials":3611,"activeCount":12},[],{"trials":3613,"activeCount":12},[],{"intervention":805,"totalTrials":33,"cells":3615},{"EARLY_PHASE1":3616,"PHASE1":3618,"PHASE2":3620,"PHASE3":3630,"PHASE4":3632,"NA":3634},{"trials":3617,"activeCount":12},[],{"trials":3619,"activeCount":12},[],{"trials":3621,"activeCount":12},[3622,3626],{"nctId":797,"briefTitle":798,"status":201,"phases":3623,"primaryCompletion":800,"completion":382,"start":383,"enrollment":12,"conditions":3624,"interventions":3625},[85,86],[802],[148,170,150,153,423,804,155,805,806,319,317,141,142,143,144,146,807],{"nctId":426,"briefTitle":427,"status":201,"phases":3627,"primaryCompletion":429,"completion":343,"start":430,"enrollment":12,"conditions":3628,"interventions":3629},[86],[432],[155,184,139,156,140,142,143,144,145,146,148,317,336,153,434,435],{"trials":3631,"activeCount":12},[],{"trials":3633,"activeCount":12},[],{"trials":3635,"activeCount":12},[],{"intervention":374,"totalTrials":33,"cells":3637},{"EARLY_PHASE1":3638,"PHASE1":3640,"PHASE2":3642,"PHASE3":3652,"PHASE4":3654,"NA":3656},{"trials":3639,"activeCount":12},[],{"trials":3641,"activeCount":12},[],{"trials":3643,"activeCount":12},[3644,3648],{"nctId":366,"briefTitle":367,"status":201,"phases":3645,"primaryCompletion":344,"completion":369,"start":370,"enrollment":12,"conditions":3646,"interventions":3647},[86],[372],[217,152,374,153,140,142,143,144,146,375,148,317,336,294,376],{"nctId":378,"briefTitle":379,"status":201,"phases":3649,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3650,"interventions":3651},[85,86],[385],[183,149,387,388,389,374,390,391,392,393,317,140,141,142,143,144,145,146,336],{"trials":3653,"activeCount":12},[],{"trials":3655,"activeCount":12},[],{"trials":3657,"activeCount":12},[],{"intervention":3659,"totalTrials":33,"cells":3660},"250 mg\u002Fm2 aldoxorubicin",{"EARLY_PHASE1":3661,"PHASE1":3663,"PHASE2":3665,"PHASE3":3687,"PHASE4":3689,"NA":3691},{"trials":3662,"activeCount":12},[],{"trials":3664,"activeCount":12},[],{"trials":3666,"activeCount":12},[3667,3676],{"nctId":3668,"briefTitle":3669,"status":119,"phases":3670,"primaryCompletion":3671,"completion":3671,"start":3672,"enrollment":1987,"conditions":3673,"interventions":3674},"NCT02014844","Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma",[86],"2016-12","2014-03",[168],[3659,3675],"350 mg\u002Fm2 aldoxorubicin",{"nctId":3677,"briefTitle":3678,"status":119,"phases":3679,"primaryCompletion":3680,"completion":3680,"start":3681,"enrollment":3682,"conditions":3683,"interventions":3685},"NCT02235701","Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide\u002FMesna in Subjects With Metastatic Soft Tissue Sarcoma",[85,86],"2018-05-01","2014-09-02",70,[3684],"Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma",[3686,3659],"170 mg\u002Fm2 aldoxorubicin",{"trials":3688,"activeCount":12},[],{"trials":3690,"activeCount":12},[],{"trials":3692,"activeCount":12},[],{"intervention":424,"totalTrials":33,"cells":3694},{"EARLY_PHASE1":3695,"PHASE1":3697,"PHASE2":3699,"PHASE3":3709,"PHASE4":3711,"NA":3713},{"trials":3696,"activeCount":12},[],{"trials":3698,"activeCount":12},[],{"trials":3700,"activeCount":12},[3701,3705],{"nctId":418,"briefTitle":419,"status":201,"phases":3702,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3703,"interventions":3704},[85,86],[26],[148,170,150,152,153,423,155,156,424,317,142,143,146,336],{"nctId":459,"briefTitle":460,"status":201,"phases":3706,"primaryCompletion":381,"completion":382,"start":383,"enrollment":12,"conditions":3707,"interventions":3708},[85,86],[463],[148,170,150,152,153,423,155,392,465,424,317,140,142,143,145,146,336],{"trials":3710,"activeCount":12},[],{"trials":3712,"activeCount":12},[],{"trials":3714,"activeCount":12},[],{"intervention":848,"totalTrials":33,"cells":3716},{"EARLY_PHASE1":3717,"PHASE1":3719,"PHASE2":3721,"PHASE3":3731,"PHASE4":3733,"NA":3735},{"trials":3718,"activeCount":12},[],{"trials":3720,"activeCount":12},[],{"trials":3722,"activeCount":12},[3723,3727],{"nctId":841,"briefTitle":842,"status":201,"phases":3724,"primaryCompletion":381,"completion":382,"start":844,"enrollment":12,"conditions":3725,"interventions":3726},[85,86],[846],[183,170,150,152,389,184,390,391,848,443,393,319,317,140,141,142,143,144,145,146,336],{"nctId":850,"briefTitle":851,"status":201,"phases":3728,"primaryCompletion":381,"completion":382,"start":344,"enrollment":12,"conditions":3729,"interventions":3730},[85,86],[854],[183,149,387,856,153,184,390,391,848,443,393,857,317,140,141,142,143,144,145,146,336],{"trials":3732,"activeCount":12},[],{"trials":3734,"activeCount":12},[],{"trials":3736,"activeCount":12},[],{"intervention":3738,"totalTrials":113,"cells":3739},"aNK",{"EARLY_PHASE1":3740,"PHASE1":3742,"PHASE2":3744,"PHASE3":3756,"PHASE4":3758,"NA":3760},{"trials":3741,"activeCount":12},[],{"trials":3743,"activeCount":12},[],{"trials":3745,"activeCount":12},[3746],{"nctId":3747,"briefTitle":3748,"status":109,"phases":3749,"primaryCompletion":178,"completion":178,"start":3750,"enrollment":1299,"conditions":3751,"interventions":3754},"NCT02465957","QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)",[86],"2015-09-24",[3752,3753],"Stage IIIB Merkel Cell Carcinoma","Stage IV Merkel Cell Carcinoma",[3738,3755],"aNK (NK-92) + N-803",{"trials":3757,"activeCount":12},[],{"trials":3759,"activeCount":12},[],{"trials":3761,"activeCount":12},[],{"intervention":3755,"totalTrials":113,"cells":3763},{"EARLY_PHASE1":3764,"PHASE1":3766,"PHASE2":3768,"PHASE3":3774,"PHASE4":3776,"NA":3778},{"trials":3765,"activeCount":12},[],{"trials":3767,"activeCount":12},[],{"trials":3769,"activeCount":12},[3770],{"nctId":3747,"briefTitle":3748,"status":109,"phases":3771,"primaryCompletion":178,"completion":178,"start":3750,"enrollment":1299,"conditions":3772,"interventions":3773},[86],[3752,3753],[3738,3755],{"trials":3775,"activeCount":12},[],{"trials":3777,"activeCount":12},[],{"trials":3779,"activeCount":12},[],{"intervention":157,"totalTrials":113,"cells":3781},{"EARLY_PHASE1":3782,"PHASE1":3784,"PHASE2":3786,"PHASE3":3792,"PHASE4":3794,"NA":3796},{"trials":3783,"activeCount":12},[],{"trials":3785,"activeCount":12},[],{"trials":3787,"activeCount":12},[3788],{"nctId":130,"briefTitle":131,"status":109,"phases":3789,"primaryCompletion":133,"completion":134,"start":135,"enrollment":19,"conditions":3790,"interventions":3791},[85,86],[137],[139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,44],{"trials":3793,"activeCount":12},[],{"trials":3795,"activeCount":12},[],{"trials":3797,"activeCount":12},[],{"intervention":337,"totalTrials":113,"cells":3799},{"EARLY_PHASE1":3800,"PHASE1":3802,"PHASE2":3804,"PHASE3":3810,"PHASE4":3812,"NA":3814},{"trials":3801,"activeCount":12},[],{"trials":3803,"activeCount":12},[],{"trials":3805,"activeCount":12},[3806],{"nctId":325,"briefTitle":326,"status":109,"phases":3807,"primaryCompletion":328,"completion":329,"start":330,"enrollment":33,"conditions":3808,"interventions":3809},[85,86],[332,333],[335,317,140,141,142,143,144,145,146,336,148,150,151,153,184,155,217,319,337],{"trials":3811,"activeCount":12},[],{"trials":3813,"activeCount":12},[],{"trials":3815,"activeCount":12},[],{"intervention":3817,"totalTrials":113,"cells":3818},"50 mg\u002Fm2 aldoxorubicin",{"EARLY_PHASE1":3819,"PHASE1":3821,"PHASE2":3823,"PHASE3":3838,"PHASE4":3840,"NA":3842},{"trials":3820,"activeCount":12},[],{"trials":3822,"activeCount":12},[],{"trials":3824,"activeCount":12},[3825],{"nctId":3826,"briefTitle":3827,"status":119,"phases":3828,"primaryCompletion":3829,"completion":3829,"start":3830,"enrollment":1224,"conditions":3831,"interventions":3835},"NCT02029430","A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma",[86],"2016-04-25","2014-04-03",[3832,3833,3834],"Kaposi's Sarcoma","HIV Positive","AIDS",[3817,3836,3837],"100 mg\u002Fm2 aldoxorubicin","150 mg\u002Fm2 aldoxorubicin",{"trials":3839,"activeCount":12},[],{"trials":3841,"activeCount":12},[],{"trials":3843,"activeCount":12},[],{"intervention":3836,"totalTrials":113,"cells":3845},{"EARLY_PHASE1":3846,"PHASE1":3848,"PHASE2":3850,"PHASE3":3856,"PHASE4":3858,"NA":3860},{"trials":3847,"activeCount":12},[],{"trials":3849,"activeCount":12},[],{"trials":3851,"activeCount":12},[3852],{"nctId":3826,"briefTitle":3827,"status":119,"phases":3853,"primaryCompletion":3829,"completion":3829,"start":3830,"enrollment":1224,"conditions":3854,"interventions":3855},[86],[3832,3833,3834],[3817,3836,3837],{"trials":3857,"activeCount":12},[],{"trials":3859,"activeCount":12},[],{"trials":3861,"activeCount":12},[],{"intervention":3837,"totalTrials":113,"cells":3863},{"EARLY_PHASE1":3864,"PHASE1":3866,"PHASE2":3868,"PHASE3":3874,"PHASE4":3876,"NA":3878},{"trials":3865,"activeCount":12},[],{"trials":3867,"activeCount":12},[],{"trials":3869,"activeCount":12},[3870],{"nctId":3826,"briefTitle":3827,"status":119,"phases":3871,"primaryCompletion":3829,"completion":3829,"start":3830,"enrollment":1224,"conditions":3872,"interventions":3873},[86],[3832,3833,3834],[3817,3836,3837],{"trials":3875,"activeCount":12},[],{"trials":3877,"activeCount":12},[],{"trials":3879,"activeCount":12},[],{"intervention":806,"totalTrials":113,"cells":3881},{"EARLY_PHASE1":3882,"PHASE1":3884,"PHASE2":3886,"PHASE3":3892,"PHASE4":3894,"NA":3896},{"trials":3883,"activeCount":12},[],{"trials":3885,"activeCount":12},[],{"trials":3887,"activeCount":12},[3888],{"nctId":797,"briefTitle":798,"status":201,"phases":3889,"primaryCompletion":800,"completion":382,"start":383,"enrollment":12,"conditions":3890,"interventions":3891},[85,86],[802],[148,170,150,153,423,804,155,805,806,319,317,141,142,143,144,146,807],{"trials":3893,"activeCount":12},[],{"trials":3895,"activeCount":12},[],{"trials":3897,"activeCount":12},[],{"intervention":807,"totalTrials":113,"cells":3899},{"EARLY_PHASE1":3900,"PHASE1":3902,"PHASE2":3904,"PHASE3":3910,"PHASE4":3912,"NA":3914},{"trials":3901,"activeCount":12},[],{"trials":3903,"activeCount":12},[],{"trials":3905,"activeCount":12},[3906],{"nctId":797,"briefTitle":798,"status":201,"phases":3907,"primaryCompletion":800,"completion":382,"start":383,"enrollment":12,"conditions":3908,"interventions":3909},[85,86],[802],[148,170,150,153,423,804,155,805,806,319,317,141,142,143,144,146,807],{"trials":3911,"activeCount":12},[],{"trials":3913,"activeCount":12},[],{"trials":3915,"activeCount":12},[],{"intervention":3917,"totalTrials":113,"cells":3918},"AAHI-SC2 Vaccine",{"EARLY_PHASE1":3919,"PHASE1":3921,"PHASE2":3923,"PHASE3":3936,"PHASE4":3938,"NA":3940},{"trials":3920,"activeCount":12},[],{"trials":3922,"activeCount":12},[],{"trials":3924,"activeCount":12},[3925],{"nctId":3926,"briefTitle":3927,"status":109,"phases":3928,"primaryCompletion":3929,"completion":3929,"start":3930,"enrollment":3931,"conditions":3932,"interventions":3933},"NCT05370040","THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines",[85,86],"2024-03-11","2022-05-05",60,[18],[3917,3934,3935],"AAHI-SC3 Vaccine","EUA or approved vaccine",{"trials":3937,"activeCount":12},[],{"trials":3939,"activeCount":12},[],{"trials":3941,"activeCount":12},[],{"intervention":3934,"totalTrials":113,"cells":3943},{"EARLY_PHASE1":3944,"PHASE1":3946,"PHASE2":3948,"PHASE3":3954,"PHASE4":3956,"NA":3958},{"trials":3945,"activeCount":12},[],{"trials":3947,"activeCount":12},[],{"trials":3949,"activeCount":12},[3950],{"nctId":3926,"briefTitle":3927,"status":109,"phases":3951,"primaryCompletion":3929,"completion":3929,"start":3930,"enrollment":3931,"conditions":3952,"interventions":3953},[85,86],[18],[3917,3934,3935],{"trials":3955,"activeCount":12},[],{"trials":3957,"activeCount":12},[],{"trials":3959,"activeCount":12},[],{"intervention":3935,"totalTrials":113,"cells":3961},{"EARLY_PHASE1":3962,"PHASE1":3964,"PHASE2":3966,"PHASE3":3972,"PHASE4":3974,"NA":3976},{"trials":3963,"activeCount":12},[],{"trials":3965,"activeCount":12},[],{"trials":3967,"activeCount":12},[3968],{"nctId":3926,"briefTitle":3927,"status":109,"phases":3969,"primaryCompletion":3929,"completion":3929,"start":3930,"enrollment":3931,"conditions":3970,"interventions":3971},[85,86],[18],[3917,3934,3935],{"trials":3973,"activeCount":12},[],{"trials":3975,"activeCount":12},[],{"trials":3977,"activeCount":12},[],{"intervention":376,"totalTrials":113,"cells":3979},{"EARLY_PHASE1":3980,"PHASE1":3982,"PHASE2":3984,"PHASE3":3990,"PHASE4":3992,"NA":3994},{"trials":3981,"activeCount":12},[],{"trials":3983,"activeCount":12},[],{"trials":3985,"activeCount":12},[3986],{"nctId":366,"briefTitle":367,"status":201,"phases":3987,"primaryCompletion":344,"completion":369,"start":370,"enrollment":12,"conditions":3988,"interventions":3989},[86],[372],[217,152,374,153,140,142,143,144,146,375,148,317,336,294,376],{"trials":3991,"activeCount":12},[],{"trials":3993,"activeCount":12},[],{"trials":3995,"activeCount":12},[],{"intervention":229,"totalTrials":113,"cells":3997},{"EARLY_PHASE1":3998,"PHASE1":4000,"PHASE2":4002,"PHASE3":4008,"PHASE4":4010,"NA":4012},{"trials":3999,"activeCount":12},[],{"trials":4001,"activeCount":12},[],{"trials":4003,"activeCount":12},[4004],{"nctId":220,"briefTitle":221,"status":201,"phases":4005,"primaryCompletion":223,"completion":223,"start":224,"enrollment":12,"conditions":4006,"interventions":4007},[85,86],[226,227],[140,144,147,183,150,153,184,155,156,229,230,142,143,145,146,151,44],{"trials":4009,"activeCount":12},[],{"trials":4011,"activeCount":12},[],{"trials":4013,"activeCount":12},[],{"intervention":408,"totalTrials":113,"cells":4015},{"EARLY_PHASE1":4016,"PHASE1":4018,"PHASE2":4020,"PHASE3":4026,"PHASE4":4028,"NA":4030},{"trials":4017,"activeCount":12},[],{"trials":4019,"activeCount":12},[],{"trials":4021,"activeCount":12},[4022],{"nctId":399,"briefTitle":400,"status":119,"phases":4023,"primaryCompletion":402,"completion":402,"start":403,"enrollment":404,"conditions":4024,"interventions":4025},[85,86],[406],[408,77,217],{"trials":4027,"activeCount":12},[],{"trials":4029,"activeCount":12},[],{"trials":4031,"activeCount":12},[],{"intervention":4033,"totalTrials":113,"cells":4034},"Nogapendekin Alfa-Inbakicept",{"EARLY_PHASE1":4035,"PHASE1":4037,"PHASE2":4039,"PHASE3":4053,"PHASE4":4055,"NA":4057},{"trials":4036,"activeCount":12},[],{"trials":4038,"activeCount":12},[],{"trials":4040,"activeCount":12},[4041],{"nctId":4042,"briefTitle":4043,"status":201,"phases":4044,"primaryCompletion":4045,"completion":4046,"start":736,"enrollment":12,"conditions":4047,"interventions":4051},"NCT07492888","Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis\u002FARDS)",[86],"2026-11-15","2027-01-15",[4048,4049,28,4050],"Acute Respiratory Distress Syndrome","Severe Community-Acquired Pneum","Lymphopenia \u002F Immunoparalysis in Critically Ill Adults",[4033,4052],"Allogeneic invariant Natural Killer T",{"trials":4054,"activeCount":12},[],{"trials":4056,"activeCount":12},[],{"trials":4058,"activeCount":12},[],{"intervention":4052,"totalTrials":113,"cells":4060},{"EARLY_PHASE1":4061,"PHASE1":4063,"PHASE2":4065,"PHASE3":4071,"PHASE4":4073,"NA":4075},{"trials":4062,"activeCount":12},[],{"trials":4064,"activeCount":12},[],{"trials":4066,"activeCount":12},[4067],{"nctId":4042,"briefTitle":4043,"status":201,"phases":4068,"primaryCompletion":4045,"completion":4046,"start":736,"enrollment":12,"conditions":4069,"interventions":4070},[86],[4048,4049,28,4050],[4033,4052],{"trials":4072,"activeCount":12},[],{"trials":4074,"activeCount":12},[],{"trials":4076,"activeCount":12},[],{"intervention":3675,"totalTrials":113,"cells":4078},{"EARLY_PHASE1":4079,"PHASE1":4081,"PHASE2":4083,"PHASE3":4089,"PHASE4":4091,"NA":4093},{"trials":4080,"activeCount":12},[],{"trials":4082,"activeCount":12},[],{"trials":4084,"activeCount":12},[4085],{"nctId":3668,"briefTitle":3669,"status":119,"phases":4086,"primaryCompletion":3671,"completion":3671,"start":3672,"enrollment":1987,"conditions":4087,"interventions":4088},[86],[168],[3659,3675],{"trials":4090,"activeCount":12},[],{"trials":4092,"activeCount":12},[],{"trials":4094,"activeCount":12},[],{"intervention":1955,"totalTrials":113,"cells":4096},{"EARLY_PHASE1":4097,"PHASE1":4099,"PHASE2":4101,"PHASE3":4107,"PHASE4":4109,"NA":4111},{"trials":4098,"activeCount":12},[],{"trials":4100,"activeCount":12},[],{"trials":4102,"activeCount":12},[4103],{"nctId":1946,"briefTitle":1947,"status":119,"phases":4104,"primaryCompletion":1949,"completion":1949,"start":1950,"enrollment":1951,"conditions":4105,"interventions":4106},[86],[1953],[375,1955],{"trials":4108,"activeCount":12},[],{"trials":4110,"activeCount":12},[],{"trials":4112,"activeCount":12},[],{"intervention":434,"totalTrials":113,"cells":4114},{"EARLY_PHASE1":4115,"PHASE1":4117,"PHASE2":4119,"PHASE3":4125,"PHASE4":4127,"NA":4129},{"trials":4116,"activeCount":12},[],{"trials":4118,"activeCount":12},[],{"trials":4120,"activeCount":12},[4121],{"nctId":426,"briefTitle":427,"status":201,"phases":4122,"primaryCompletion":429,"completion":343,"start":430,"enrollment":12,"conditions":4123,"interventions":4124},[86],[432],[155,184,139,156,140,142,143,144,145,146,148,317,336,153,434,435],{"trials":4126,"activeCount":12},[],{"trials":4128,"activeCount":12},[],{"trials":4130,"activeCount":12},[],{"intervention":260,"totalTrials":113,"cells":4132},{"EARLY_PHASE1":4133,"PHASE1":4135,"PHASE2":4137,"PHASE3":4143,"PHASE4":4145,"NA":4147},{"trials":4134,"activeCount":12},[],{"trials":4136,"activeCount":12},[],{"trials":4138,"activeCount":12},[4139],{"nctId":251,"briefTitle":252,"status":109,"phases":4140,"primaryCompletion":254,"completion":255,"start":256,"enrollment":24,"conditions":4141,"interventions":4142},[85,86],[258],[44,171,260,153],{"trials":4144,"activeCount":12},[],{"trials":4146,"activeCount":12},[],{"trials":4148,"activeCount":12},[],{"intervention":3585,"totalTrials":113,"cells":4150},{"EARLY_PHASE1":4151,"PHASE1":4153,"PHASE2":4155,"PHASE3":4161,"PHASE4":4163,"NA":4165},{"trials":4152,"activeCount":12},[],{"trials":4154,"activeCount":12},[],{"trials":4156,"activeCount":12},[4157],{"nctId":3573,"briefTitle":3574,"status":119,"phases":4158,"primaryCompletion":3576,"completion":3577,"start":3578,"enrollment":3579,"conditions":4159,"interventions":4160},[86],[3581,3582,3583],[3544,3585],{"trials":4162,"activeCount":12},[],{"trials":4164,"activeCount":12},[],{"trials":4166,"activeCount":12},[],{"intervention":270,"totalTrials":113,"cells":4168},{"EARLY_PHASE1":4169,"PHASE1":4171,"PHASE2":4173,"PHASE3":4179,"PHASE4":4181,"NA":4183},{"trials":4170,"activeCount":12},[],{"trials":4172,"activeCount":12},[],{"trials":4174,"activeCount":12},[4175],{"nctId":262,"briefTitle":263,"status":109,"phases":4176,"primaryCompletion":265,"completion":266,"start":267,"enrollment":179,"conditions":4177,"interventions":4178},[86],[26],[148,44,270],{"trials":4180,"activeCount":12},[],{"trials":4182,"activeCount":12},[],{"trials":4184,"activeCount":12},[],{"intervention":474,"totalTrials":113,"cells":4186},{"EARLY_PHASE1":4187,"PHASE1":4189,"PHASE2":4191,"PHASE3":4197,"PHASE4":4199,"NA":4201},{"trials":4188,"activeCount":12},[],{"trials":4190,"activeCount":12},[],{"trials":4192,"activeCount":12},[4193],{"nctId":467,"briefTitle":468,"status":109,"phases":4194,"primaryCompletion":470,"completion":357,"start":471,"enrollment":24,"conditions":4195,"interventions":4196},[85,86],[15],[153,319,150,184,155,392,149,183,317,474,140,144],{"trials":4198,"activeCount":12},[],{"trials":4200,"activeCount":12},[],{"trials":4202,"activeCount":12},[],{"intervention":3686,"totalTrials":113,"cells":4204},{"EARLY_PHASE1":4205,"PHASE1":4207,"PHASE2":4209,"PHASE3":4215,"PHASE4":4217,"NA":4219},{"trials":4206,"activeCount":12},[],{"trials":4208,"activeCount":12},[],{"trials":4210,"activeCount":12},[4211],{"nctId":3677,"briefTitle":3678,"status":119,"phases":4212,"primaryCompletion":3680,"completion":3680,"start":3681,"enrollment":3682,"conditions":4213,"interventions":4214},[85,86],[3684],[3686,3659],{"trials":4216,"activeCount":12},[],{"trials":4218,"activeCount":12},[],{"trials":4220,"activeCount":12},[],{"intervention":4222,"totalTrials":113,"cells":4223},"Neukoplast™",{"EARLY_PHASE1":4224,"PHASE1":4226,"PHASE2":4237,"PHASE3":4239,"PHASE4":4241,"NA":4243},{"trials":4225,"activeCount":12},[],{"trials":4227,"activeCount":12},[4228],{"nctId":4229,"briefTitle":4230,"status":119,"phases":4231,"primaryCompletion":4232,"completion":4232,"start":4233,"enrollment":1299,"conditions":4234,"interventions":4236},"NCT00900809","QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia",[85],"2015-06-02","2014-05-12",[4235],"Acute Myeloid Leukemia",[4222],{"trials":4238,"activeCount":12},[],{"trials":4240,"activeCount":12},[],{"trials":4242,"activeCount":12},[],{"trials":4244,"activeCount":12},[],{"intervention":4246,"totalTrials":113,"cells":4247},"BM-Allo.MSC",{"EARLY_PHASE1":4248,"PHASE1":4250,"PHASE2":4261,"PHASE3":4263,"PHASE4":4265,"NA":4267},{"trials":4249,"activeCount":12},[],{"trials":4251,"activeCount":12},[4252],{"nctId":4253,"briefTitle":4254,"status":109,"phases":4255,"primaryCompletion":4256,"completion":4256,"start":4257,"enrollment":19,"conditions":4258,"interventions":4260},"NCT04397796","Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation",[85],"2020-09-06","2020-08-03",[4259],"COVID",[4246],{"trials":4262,"activeCount":12},[],{"trials":4264,"activeCount":12},[],{"trials":4266,"activeCount":12},[],{"trials":4268,"activeCount":12},[],{"intervention":1990,"totalTrials":113,"cells":4270},{"EARLY_PHASE1":4271,"PHASE1":4273,"PHASE2":4279,"PHASE3":4281,"PHASE4":4283,"NA":4285},{"trials":4272,"activeCount":12},[],{"trials":4274,"activeCount":12},[4275],{"nctId":1981,"briefTitle":1982,"status":109,"phases":4276,"primaryCompletion":1984,"completion":1985,"start":1986,"enrollment":1987,"conditions":4277,"interventions":4278},[85],[21],[1974,1990],{"trials":4280,"activeCount":12},[],{"trials":4282,"activeCount":12},[],{"trials":4284,"activeCount":12},[],{"trials":4286,"activeCount":12},[],{"intervention":4288,"totalTrials":113,"cells":4289},"haNK™ for",{"EARLY_PHASE1":4290,"PHASE1":4292,"PHASE2":4302,"PHASE3":4304,"PHASE4":4306,"NA":4308},{"trials":4291,"activeCount":12},[],{"trials":4293,"activeCount":12},[4294],{"nctId":4295,"briefTitle":4296,"status":119,"phases":4297,"primaryCompletion":4298,"completion":4298,"start":4299,"enrollment":16,"conditions":4300,"interventions":4301},"NCT03027128","QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors",[85],"2019-05-06","2017-08-02",[32],[4288],{"trials":4303,"activeCount":12},[],{"trials":4305,"activeCount":12},[],{"trials":4307,"activeCount":12},[],{"trials":4309,"activeCount":12},[],{"intervention":4311,"totalTrials":113,"cells":4312},"rMBCG",{"EARLY_PHASE1":4313,"PHASE1":4315,"PHASE2":4317,"PHASE3":4319,"PHASE4":4321,"NA":4323},{"trials":4314,"activeCount":12},[],{"trials":4316,"activeCount":12},[],{"trials":4318,"activeCount":12},[],{"trials":4320,"activeCount":12},[],{"trials":4322,"activeCount":12},[],{"trials":4324,"activeCount":12},[4325],{"nctId":4326,"briefTitle":4327,"status":4328,"phases":4329,"conditions":4330,"interventions":4331},"NCT06810141","ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer","AVAILABLE",[],[23],[4311],{"intervention":4333,"totalTrials":113,"cells":4334},"nogapendekin-alfa inbakicept",{"EARLY_PHASE1":4335,"PHASE1":4337,"PHASE2":4339,"PHASE3":4341,"PHASE4":4343,"NA":4345},{"trials":4336,"activeCount":12},[],{"trials":4338,"activeCount":12},[],{"trials":4340,"activeCount":12},[],{"trials":4342,"activeCount":12},[],{"trials":4344,"activeCount":12},[],{"trials":4346,"activeCount":12},[4347],{"nctId":4348,"briefTitle":4349,"status":4328,"phases":4350,"conditions":4351,"interventions":4352},"NCT06956547","Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and\u002For Radiation Therapy",[],[30],[4333]]